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Integrase strand transfer inhibitor (InSTI)-based regimens are now widely recommended 
as first-line antiretroviral therapy (ART) for adults with human immunodeficiency virus. But 
evidence on long-term clinical effectiveness of InSTI-based regimens remains limited.  
Using prospective pooled cohort data from the North American AIDS Cohort 
Collaboration on Research and Design (NA-ACCORD) during 2009-2016, we identified the 
participants who initiated their first ART regimen, containing either InSTI (i.e., raltegravir, 
dolutegravir, and elvitegravir/cobicstat) or efavirenz (EFV) as an active comparator, and 
estimated the long-term effects of InSTI-based regimens on virologic and clinical outcomes 
compared with the EFV-based regimen. We used inverse probability of treatment and censoring 
weights to account for baseline confounding, differential loss to follow-up and treatment 
changes, and estimated observational analogs to the intention-to-treat and per-protocol effects.  
For the virologic outcomes (i.e., viral suppression), the intention-to-treat analysis showed 
81.3% of the patients in the InSTI group and 67.3% of those in the EFV group experienced viral 
suppression at 0.25 years after ART initiation, corresponding with a difference of 14.0% (95% 
CI: 12.4, 15.6). By 1 year after ART initiation, the proportion virally suppressed was 89.5% in 
the InSTI group and 90.2% in the EFV group, corresponding with a difference of -0.7% (95% 




InSTI group, and 92.5% in the EFV group, corresponding with a difference of 2.0% (95% CI: -
7.3, 11.3). The results of per-protocol analyses were similar to the intention-to-treat analyses. 
For the clinical outcomes (i.e., composite outcomes of AIDS-defining illnesses, death, 
and serious non-AIDS events), during the 6-year follow-up, 440 of the InSTI group and 1,097 of 
the EFV group incurred the composite outcome. The 6-year intention-to-treat risks were 14.6% 
for the InSTI group and 14.3% for the EFV group, corresponding with a RD of 0.3 percentage 
point (95% CI: -2.7, 3.3), and HR was 1.08 (95% CI: 0.97, 1.19); the 6-year per-protocol risks 
were 12.2% for the InSTI group and 11.9% for the EFV group, corresponding with a RD was 0.3 
percentage point (95% CI: -3.0, 3.7), and HR was 1.09 (95% CI: 0.96, 1.25). 
Our studies showed that although InSTI-based initial ART regimens had a more rapid 
viral response compared with the EFV-based initial ART regimen, the long-term effects on 
virologic and clinical outcomes were similar. Along with the increasing studies showing the 
potential adverse effects associated with InSTI, our results on relatively similar long-term effects 
bring into question whether InSTI-based regimens should be favored over other regimens, 
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CHAPTER 1: INTRODUCTION 
 
1.1 Brief overview of human immunodeficiency virus  
Human immunodeficiency virus (HIV), a member of the genus Lentivirus, is a causative 
agent of the spectrum of disease known as acquired immunodeficiency syndrome (AIDS). HIV is 
a retrovirus that infects the human immune system by binding to the CD4 receptor and 
chemokine coreceptors of host cells, which are primary found on CD4 T cells, but also on 
monocytes and macrophages, and dendritic cells.1  
Once entering the host cell, the virus starts the replication process with the help of several 
virally encoded enzymes, including reverse transcriptase, protease, ribonuclease and integrase. 
The reverse transcriptase transcribes the uncoating viral RNA into double-stranded proviral 
DNA.2 The resulting proviral DNA then is then imported into the cell nucleus and integrated into 
the cellular RNA by the integrase, where it is transcribed by host cell to produce viral proteins 
and genomic RNA.2 Finally, the protease cleaves the viral proteins, and assembles them with 
genomic RNA into new virus particles, which is then released and begin the replication cycle 
anew.2  
 The major cause for AIDS progression in patients living with HIV is the decline of CD4 
T-cells. As a consequence of progressive depletion of CD4 T cells, the immune system is 
damaged, and becomes incapable of controlling opportunistic infections that ultimately lead to 
life-threatening AIDS-defining diseases.1 HIV infection is also characterized by a notable 
increase in immune activation, which involves both the adaptive and innate immune systems.1 




interferon-α. Second, microbial translocation, due to the profound depletion of CD4 T cells in the 
gastrointestinal tract and enhanced gastrointestinal tract permeability, leads to increased plasma 
concentration of lipopolysaccharides as a potent activator of TLR4, which results in the 
production of pro-inflammatory cytokines such as interleukin 6 and tumor necrosis factor α. 
Further, coinfection with viruses such as cytomegalovirus can induce marked expansion of active 
cytomegalovirus-specific T cells. There is a growing body of evidence of residual inflammation 
and increased immune activation even among patients with HIV on antiretroviral therapy.1 
Residual chronic inflammation in patients with HIV on antiretroviral therapy has been associated 
with increased mortality3 and non-AIDS related diseases including (but not limited to) 
cardiovascular disease4, cancer5, neurological disease6, liver disease7, and depression8.   
 HIV is spread primarily through unprotected sex, mother to child transmission, 
contaminated blood transfusion, injection drug use, accidental inoculation, or organ 
transplantation.9 An important factor in the likelihood of HIV transmission is plasma HIV viral 
load. Acute HIV infection, which causes a high concentration of plasma viral load early after 
infection (while patients are asymptomatic, and even remain antibody-negative), is a significant 
driver of HIV epidemics.1 Thus the goal of HIV treatment is to reduce the HIV viral load to a 
consistently undetectable level. Other prognostic factors that increase the risk of sexual 
transmission of HIV include (but not limited to) sexually transmitted infections, pregnancy, 
multiple sexual partners, concurrent relationships, and injection drug use.1 
 The World Health Organization estimates that 37.9 million people were living with HIV 
globally and it resulted in 770,000 deaths in 2018.10 The African region remains most severely 
affected, which accounted for more than two-thirds of the people living with HIV worldwide. 




1.1 million people living with HIV in the United States in 2016, of whom about 14% were not 
aware of their HIV status.  
 
1.2 Antiretroviral therapy  
The introduction of combination antiretroviral therapy (ART) in the mid-1990s brought 
about dramatic decline in AIDS diagnoses and deaths. Contemporary ART is highly effective in 
suppressing plasma viremia and prolonging survival, making HIV infection a manageable 
chronic disease.11 Contemporary ART is usually composed of two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus a third active drug of different class (a nonnucleoside 
reverse transcriptase [NNRTI; e.g., efavirenz], a boosted protease inhibitor [PI; e.g., atazanavir 
or darunavir], or an integrase strand transfer inhibitor [InSTI; e.g., raltegravir]). Because there is 
no current strategy for HIV cure, people with HIV infection may be exposed to ART for decades. 
Maximizing the safety profile and tolerability while maintaining strong potency of ART is a 
clinical priority.  
The NNRTI-class efavirenz (EFV)-based regimen was recommended as the preferred 
first-line regimen for people with HIV for over fifteen years.12 Like other NNRTIs, EFV restricts 
HIV viral replication by binding to and blocking the hydrophobic region of the HIV-1 reverse 
transcriptase via a mechanism that alters the enzyme conformation. Currently, EFV-based 
regimens are still one of the most commonly prescribed antiretroviral medications worldwide.12 
Almost 70% of people on a first-line regimen, especially in low- and middle-income countries, 
were using EFV-based combinations by 2014.12 Numerous head-to-head randomized clinical 
trials have demonstrated the efficacy and short-term safety of EFV.13–18 One of the major 




disoproxil fumarate (TDF) and emtricitabine (FTC) - into a convenient single-pill, once daily 
regimen, the first single tablet ART regimen approved in the US. Such formulation has potential 
for improved adherence to antiretroviral medications. Based on the high virologic efficacy and 
safety in clinical trials combined with ease of administration, EFV-based regimens have long 
been among the most frequently employed ART regimens to treat HIV-infection.  
Despite its advantages, growing evidence has shown EFV is associated with several long-
term adverse events, especially in terms of the central nervous system.19–21 EFV has been 
associated with neuropsychological side effects, including decreased concentration, dizziness, 
and vivid dreams. Some studies also found increased risks of depression and suicidal ideation for 
people taking EFV.22,23 Furthermore, EFV was related to neurocognitive impairment, although 
the evidence was mixed.22,24 In addition, it has been recognized that transmitted resistance is an 
important concerns for EFV. Because of these issues, the primacy of EFV has been challenged 
by newer potent drugs that have been tested in randomized trials to demonstrate a better 
toxicological profile and result in more desirable patient tolerance, a critical factor in the present 
era of lifelong HIV management. As a result, the current US Department of Health and Human 
Services (DHHS) guidelines have removed EFV from the first-line treatment therapy 
recommendation list.  
InSTI-based regimens are one of the most recently developed and promising classes of 
antiretroviral drugs, and have gained increasing popularity in the developed world since the FDA 
approved the first InSTI, raltegravir, in 2007. InSTI-class drugs inhibit the catalytic activity of 
HIV-encoded viral enzyme integrase and block the insertion of HIV genome into the DNA of 
host cell, thus halting the spread of HIV virus. Randomized comparative trials have 




[DTG, FDA approved in 2013], elvitegravir/cobicistat [EVG/COBI, FDA approved in 2012], 
and bictegravir [BIC] FDA approved in 2018) experience more rapid and potent antiretroviral 
activity, and fewer adverse events and drug interactions compared with those initiating other 
regimens.25–33 In addition, the current available InSTIs, except RAL with no fixed-dose 
formulation, can be administered as a once-daily, single-tablet regimens, hence reducing the pill 
burden and promoting therapy adherence. An overview of each InSTI-class drug is described in 
Table 1.1.  
Because of these advantages, the US Department of Health and Human Services, the 
International Antiviral Society-USA and the European antiretroviral treatment guidelines all now 
recommend InSTI-based regimens for adults.12,34 Particularly, treatment guideline panels have 
recommended InSTI-based regimens as initial ART therapy.34,35 The WHO added DTG to its 
first-line regimen list in 2016 consolidated guidelines for the use of antiretroviral drugs.12 
Moreover, the US President’s Emergency Plan For AIDS Relief (PEPFAR) is rolling out DTG-
based regimens to essentially replace EFV-based regimens worldwide. Although recent reports 
of neural tube defects have caused both US and WHO guidelines to caution providers about use 
of dolutegravir by individuals of childbearing potential,36 dolutegravir and other InSTI-class 
drugs remain the recommended therapy for most people with HIV. 
Direct comparisons of efficacy and safety of InSTI-based regimens with EFV-regimen 
have been performed in the randomized clinical trials: STARTMRK (RAL vs. EFV)25,37–40, 
SINGLE (DTG vs. EFV)28,41, and Study 102 (EVG vs. EFV)30,31,42,43.  A brief summary of each 
trial is presented in Table 1.2.  
The STARTMRK study25,37–40 was a multicenter, double blind, phase III, non-inferiority 




enrolled, stratified by baseline screening HIV RNA levels (>50,000 vs. <= 50,000 copies/ml) and 
randomized (1:1 ratio) to RAL twice daily or EFV once daily, both combined with the TDF/FTC  
backbone. The primary endpoint was achievement of less than 50 viral RNA copies/ml at week 
48. Secondary endpoints included the proportion of patients achieving viral load <400 copies/ml 
and change from baseline in CD4 counts both measured at week 48 and 96, as well as achieving 
viral load <50 copies/ml at week 96. The main analysis showed that, at week 48, 86.1% of the 
RAL group and 81.9% of the EFV group achieved viral suppression <50 copes/ml. The time to 
achieve viral suppression was significantly shorter for patients on RAL than on EFV. The RAL 
group patients also presented significantly fewer drug-related clinical adverse events (44.1%) 
compared with those on EFV (77.0%). The results at week 96 and 156 also supported the non-
inferiority of RAL, and these results further found that treatment effects were consistent across 
subgroups stratified by pre-specified demographic and prognostic characteristics. The final 
results at week 192 and 240 when the study maintained blinded showed that based on a 
subsequent test of superiority following the condition that non-inferiority was met, RAL induced 
a significantly better viral suppression than EFV (71.0% vs. 61.3% at week 240), and the RAL 
recipients also experienced significantly fewer drug-related clinical adverse events as well as 
neuropsychiatric side effects, proving the superiority of RAL/ TDF/FTC compared with 
EFV/TDF/FTC. 
The SINGLE study28,41 was a randomized, double-blind, multicenter phase III non-
inferiority clinical trial directly comparing efficacy and safety of DTG plus abacavir/lamivudine 
(ABC/3TC) fixed-dose combination with the co-formulated EFV/TDF/FTC among 844 
treatment-naïve subjects with viral load >1,000 copies/ml and negative for the HLA-B*5701 




cell count (> vs. ≤ 200/mm3), and randomly assigned (1:1) to either DTG/ABC/3TC or 
EFV/FTC/TDF. The primary endpoint was the proportion of participants achieving viral 
suppression (viral load <50 copies/ml) at week 48, with a 10% non-inferiority margin. If both 
per-protocol and intention-to-treat showed non-inferiority, superiority test was then conducted. 
At week 48, the DTG/ABC/3TC group had a significantly higher proportion of participants 
achieving viral suppression (88%) compared with the EFV/FTC/TDF group (81%). The 
DTG/ABC/3TC also experienced a shorter median time to viral suppression than did the 
EFV/FTC/TDF group (28 vs. 84 days), as well as a better immune recovery (267 vs. 208 CD4 
count/mm3). Lower rate of treatment discontinuation due to adverse events was found in the 
DTG/ABC/3TC group than in the EFV/FTC/TDF group (2% vs. 10%). Furthermore, 
DTG/ABC/3TC has a more favorable tolerability profile than EFV/FTC/TDF with a lower rate 
of rash and neuropsychiatric events (whereas higher rate of insomnia was found in the 
DTG/ABC/3TC group). Such treatment effect was found to be consistent in HIV-infected 
participants with a variety of baseline characteristics. In addition, no participant incurred 
emergence of resistant virus in the DTG/ABC/3TC arm, while five participants have virus with 
resistance detected in the EFV/TDF/FTC arm (one TDF-associated mutation and four 
EFV/associated mutations). At week 96 and 144, DTG/ABC/3TC remained superior. 71% in the 
DTG/ABC/3TC group and 63% in the EFV/TDF/FTC group maintained virally suppressed. In 
addition, before this phase 3 assessment, a phase-2b, dose-ranging randomized trials -- the 
SPRING-1 study --44,45 was conducted to select a dose for DTG. Briefly, 205 patients were 
randomized (1:1:1:1) to receive 10 mg, 25 mg, and 50 mg DTG, respectively, or to receive EFV. 




The Study 10230,31,42,43 was a phase II clinical trial conducted among treatment-naïve 
patients comparing the safety and efficacy of co-formulated EVG/COBI/FTC/TDF versus co-
formulated EFV/FTC/TDF. Eligible participants should have plasma HIV RNA ≥5000 copes/ml, 
an estimated glomerular filtration rate (eGFR) ≥70 ml/min, and be susceptible to EFV, TDF, and 
FTC by HIV-1 genotype at screening. 700 eligible patients were randomized (1:1 ratio) to 
receive either EVG/COBI/FTC/TDF or EFV/FTC/TDF with matched tablets. The primary 
endpoint was the proportion of patients in the intention-to-treat population with viral suppression 
(HIV RNA <50 copies/ml) at week 48 according to a snapshot analysis, with a 12% non-
inferiority margin. At week 48, 87.6% in the EVG/COBI/FTC/TDF group and 84.1% in the 
EFV/FTC/TDF group achieved viral suppression, suggesting non-inferiority of 
EVG/COBI/FTC/TDF. Response rates were similar in the EVG/COBI/FTC/TDF group and in 
the EFV/FTC/TDF group among subgroups of patients stratified by demographic and prognostic 
factors. Significantly better immunological recovery was found in the EVG/COBI/FTC/TDF 
group than in the EFV/FTC/TDF group (CD4 increase: 239/mm3 vs. 206/mm3). FDA-defined 
time to loss of virologic response analysis in the intention-to-treat population confirmed that rate 
of achievement and maintenance of viral suppression was comparable between the two groups 
(85.9% in the EVG/COBI/FTC/TDF group and 83.2% in the EFV/FTC/TDF group). Similar 
number of treatment discontinuations due to adverse events occurred in each group (3.7% in the 
EVG/COBI/FTC/TDF group and 5.1% in the EFV/FTC/TDF group). The most frequent adverse 
events were nausea (more common with EVG/COBI/FTC/TDF [20.7%] than with 
EFV/FTC/TDF [13.3%] and dizziness (6.6% vs. 24.4%). Other adverse events that were less 




to show the comparable rates of viral suppression as well as treatment discontinuation in the two 
groups.  
However, these randomized clinical trials that supported the current guidelines focused 
on short-term biomarkers including HIV viral suppression and CD4+ cell count change. HIV 
RNA viral load, and to a lesser extent CD4+ cell count, are excellent HIV biomarkers and are 
often used in HIV trials, but it has been long appreciated that no surrogate biomarker is fully 
adequate to predict clinical HIV progression.46–50 According to Prentice’ criteria51, a “true” rare 
or distal clinical endpoint can be replaced by a more frequent or proximate surrogate endpoint in 
randomized trials to reduce the sample size or trial duration. But it is required that the surrogate 
biomarker should not only be strong predictor of clinical endpoint, but should also capture the 
net treatment effect on the clinical endpoint.51–53 That is, the surrogate biomarker should capture 
effect aggregated over all mechanisms of action of the treatment on the clinical endpoint. In 
practice, however, effects on surrogate biomarker often do not predict the true clinical effects.52 
For instance, there may exist some causal pathways of the disease process that are not mediated 
through the surrogate biomarker but are influenced by intervention under unintended 
mechanisms. Further, short-term follow up using surrogate biomarkers in randomized trials may 
not be able to estimate the long-term clinical adverse events associated with switching or 
discontinuation of treatment that occurs after the study’s conclusion. Therefore, to more fully 
understand the effectiveness of InSTI-based regimens, evidence is needed concerning the impact 
of InSTIs on long-term clinical outcomes, including AIDS-defining illnesses and all-cause 
mortality. Existing randomized trials, however, are underpowered to study long-term clinical 
outcomes. Observational studies, especially prospective cohort studies, are the only feasible way 




an InSTI-based regimen (RAL) on long-term clinical outcomes like incident AIDS and death. 
This study had a relatively small number of patients initiating InSTI-regimens and was restricted 
to 4-year follow-up.54 Further, existing observational studies are focused on AIDS related 
conditions and death as the outcome, and have not characterized the impact of InSTI-based 
regimens on serious non-AIDS conditions.55–57 Given limitations of the existing randomized 
trials and cohort studies, large datasets with long-term clinical outcomes including AIDS-
defining illnesses, serious non-AIDS events, and death on InSTI-based regimens are needed.  
Additionally, recent publications indicate possible associations between InSTIs and other 
important adverse events in real-life settings, including muscular toxicity, neuropsychiatric 







Table 1.1: Advantages and disadvantages of currently available InSTIs 
Drug Advantages Disadvantages 
Raltegravir   Few drug interactions 
 Longest safety record with more 
clinical experience 
 Administration with or without 
food  
 Rapid drop in viral load 
 No interactions with anti-HCV 
DAA agents 
 
 Higher pill burden 
 No single-tablet complete 
formulation with other NRTIs 
 Lower genetic barrier than 
bictegravir and dolutegravir 
 Inferior to dolutegravir in 
treatment-experienced patients 
with HIV RNA >100,000 
copies/ml 
 Potential muscular toxicity 
 Potential neural tube defects 
Elvitegravir   Once-daily dosing 
 Available as single-tablet complete 
regimen  
 Rapid drop in viral load 
 Require pharmacological boosting 
of cobicistat, potential CYP3A 
inhibitor 
 Substantial drug interactions due 
to cobicistat 
 Cobicistat raises serum creatinine 
levels due to inhibition of tabular 
secretion of creatinine 
 Not recommended for patients 
with eGFR <70ml/min 
 Lower genetic barrier than 
dolutegravir 
 Must be administered with food 
 Interactions with anti-HCV DAA 
agents 
 Should be avoided in pregnant 
women because of inadequate 
plasma levels 
 Potential neural tube defects 
Dolutegravir  Once-daily dosing with or without 
food 
 Available as single-tablet complete 
regimen 
 Rapid drop in viral load 
 Superior to raltegravir in treatment-
experienced patients 
 Long half-life: 
 High genetic barrier; low risk of 
resistance with virologic failure 
 Relatively few drug interactions 
 Rise in serum creatinine levels due 
to inhibition of the OCT-2 
transporter 
 Higher risk of neuropsychiatric 
adverse effects reported in some 
observational studies 
 Coformulated with 
abcavir/lamivudine; abacavir 
requires HLA-B*5701 testing, and 
has been associated with 




 No interactions with anti-HCV 
DAA agents 
 Drug interactions with rifampicin 
(drug to treat tuberculosis), and 
metformin; need to adjust dosage. 
 Less clinical experience compared 
to RAL 
 Potential neural tube defects 
Bictegravir  Once-daily dosing with or without 
food 
 Available as single-tablet complete 
regimen 
 Non-inferior to dolutegravir 
 High genetic barrier; low risk of 
resistance with virologic failure 
 Relatively few drug interactions 
 Cannot be used with rifampin 
 Limited clinical experience 






Table 1.2: Summary of randomized trials comparing InSTIs with EFV 
Study characteristics 
STARTMRK25,37–40 
(RAL vs. EFV) 
SINGLE28,41 
(DTG vs. EFV) 
Study 102 
(EVG vs. EFV) 
NRTI backbone  TDF/FTC 
ABC/3TC 
(TDF/FTC for EFV) 
TDF/FTC 
Total number of patients 566 833 700 
Female, % 19 16 11 









Non-inferiority margin 12% 10% 12% 
Viral suppression 
proportion at week 48, % 
86.1 vs. 81.9 88 vs. 81 87.6 vs. 84.1 
Difference in viral 
suppression proportion 
(95% CI) at week 48, % 
4.2 (-1.9, 10.3) 7 (2, 12) 3.6 (-1.6, 8.8) 
Treatment discontinuation 
due to adverse events, % 
2.6 vs. 6.0 2.4 vs. 10.0 3.7 vs. 5.1 
Viral suppression 
proportion at week 96, % 
81 vs. 79 80 vs. 72 84.2 vs. 81.5 
Difference in viral 
suppression proportion 
(95% CI) at week 96, % 
2 (-4, 9) 8 (2.3, 13.8) 2.7 (-2.9, 8.3) 
Viral suppression 
proportion at week 144 or 
240, % 
71.0 vs. 61.3 71 vs 63 82.2 vs 78.1 
Difference in viral 
suppression proportion 
(95% CI) at week 144 or 
240, % 
9.5 (1.7, 17.3) 8 (2.0, 14.6) 4.1 (-1.9, 10.0) 
Study Conclusion 
RAL was non-
inferior at week 48 
and 96 among 
treatment-naïve 
patients (was superior 
















CHAPTER 2: STATEMENT OF SPECIFIC AIMS 
 
2.1 Specific Aims and Rationale 
 To explore the long-term comparative effectiveness of InSTI-based HIV treatment 
regimens, we use a pooled project of observational cohort data to address the following aims: 
AIM 1 
To replicate and extend randomized evidence by examining the effect of InSTI-
based HIV treatment regimens on surrogate biomarker outcomes (i.e., HIV viral 
suppression) compared with an EFV-based regimen as an active comparator.70  
Rationale: Previous randomized trials have demonstrated that InSTI-based regimens had 
a more rapid viral response compared with EFV-based regimens.27–29 However, the primary 
results of these trials were focused on short term viral outcomes (48 weeks). Long-term virologic 
effect of InSTI-based regimens have not been fully examined. With no randomized evidence 
forthcoming, observational studies provide a unique opportunity to examine the long-term 
virologic outcomes. The new user design along with the modern per-protocol analyses via causal 
inference methods enable us to better utilize the observational data to mimic a randomized 
trial.71–73 Availability of these outcome data allows us to examine the effect on these biomarkers 
with follow-up extended beyond the trial timelines. Based on previous randomized evidence27–29, 
we hypothesize that the InSTI-based regimens will have a more rapid effect on HIV viral 
suppression (proportion of patients with HIV viral load <50 copies/ml) and favorable mean 





AIM 2  
To evaluate the comparative effectiveness of InSTI-based HIV treatment regimens 
on long-term clinical endpoints including AIDS-defining illnesses, serious non-AIDS events 
and all-cause mortality compared to EFV-based regimens.  
Rationale: This study will include HIV-seropositive patients who started a first-observed 
antiretroviral regimen consisting of emtricitabine, tenofovir disoproxil fumarate (or tenofovir 
alafenamide), and either InSTI (i.e., raltegravir, dolutegravir and elvitegravir/cobicistat) or EFV 
between 2007 and 2017. We will estimate the observational analogs to the intention-to-treat 
effect as well as the per-protocol effect. We hypothesize that the InSTI-based regimens will 










                      CHAPTER 3: METHODS 
 
3.1 Study design 
The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) includes 25 contributing single and multisite clinical and interval epidemiologic HIV 
cohorts of over 150,000 HIV-seropositive participants that encompass most HIV/AIDS cohort 
studies in the US and Canada, and is widely representative of HIV care in these two countries 
(See Figure 3.1). We have approval from NA-ACCORD to conduct this study. 
Participants of the NA-ACCORD are 29% female, 45% non-Hispanic white, 46% 
African-American/black, and 11% Hispanic. The prescription of InSTI-based regimens increased 
substantially since the FDA approved RAL in 2007. In 2015, 40% of the participants in the NA-
ACCORD were prescribed InSTI-based regimens (RAL, DTG, and EVG/COBI) while 25% 
were prescribed NNRTI-based regimens (a majority EFV-based).  
 
3.2 Study sample  
For the study aims, we include HIV-seropositive adults aged 18 or older (NA-ACCORD 
cohorts primarily collect data on adults so children cannot be studied effectively here) who 
initiated an antiretroviral regimen consisting of 2 NRTIs (i.e., TDF [or tenofovir alafenamide, 
TAF] and FTC) and either InSTI (i.e., RAL, DTG or EVG/COBI) or EFV while under follow-up 
between July 2009 and December 2016 (during 2007-2009, RAL was only recommended for 




antiretroviral treatment; 2) missing history of antiretroviral therapy; and 3) those with 
undetectable HIV RNA viral plasma viral concentration (<50 copies/ml) measured within 180 
days before to 7 days after treatment initiation (because an undetectable HIV RNA viral load 
may indicate unreported prior use of antiretroviral therapy). 
 
3.3 Preliminary data 
Prior work by Cole et al, using data from the CFAR Network of Integrated Clinical 
Systems (CNICS), assessed 4-year risk of AIDS and all-cause mortality among those initiating a 
RAL-based regimen compared to those initiating an EFV-based regimen.54 In this study, 415 
patients starting a RAL-based regimen and 2646 starting an EFV-based regimen were analyzed. 
During the 4-year follow-up period, 39 patients initiating a RAL-based regimen and 196 
initiating an EFV-based regimen incurred an AIDS-defining illness or died. 24% of patients 
dropped out from the study (i.e., lost to follow up). Results showed similar 4-year risk of AIDS 
or death. The 4-year intention-to-treat risk difference was -0.9 (95% CI: -4.5, 2.7), while the per-
protocol risk difference was -0.5 (95% CI: -3.8, 2.9) with no significant difference. However, 
this study was limited to RAL, was small (with only 39 events in the RAL group), was limited to 
AIDS incidence and mortality, and was relatively short. Thus, the proposed aims using NA-
ACCORD data, with various InSTI (including DTG, whose genetic barrier to resistance exceeds 
those of EFV, EVG and RAL35), larger sample size, and longer follow-up will address existing 






3.4 Measurements  
Initiation of InSTI-based or EFV-based regimens 
Initiation of InSTI-based regimens is defined as the date between July 2009 and 
December 2016 at which a patient initiated ART regimens consisting of TDF (or TAF) and FTC 
backbones, and one InSTI (i.e., RAL, DTG, EVG/COBI), with all drugs started within 14 days of 
each other. To be consistent with the InSTI-based regimens in terms of calendar time, initiation 
of EFV-based regimens is defined as the date between July 2009 and December 2016 at which a 
patient initiated ART regimens consisting of TDF (or TAF) and FTC backbones, and EFV with 
all drugs started within 14 days of each other. All the antiretroviral regimens used will be 
abstracted from point-of-care electronic medical records. 
 
Outcomes of interest 
The primary outcome for Aim 2 is the combined clinical outcomes used by the START 
trial.74 Specifically, the AIDS-defining illnesses (e.g., non-Hodgkin lymphoma, progressive 
multifocal leukoencephalopathy, cryptococcosis, cerebral toxoplasmosis, AIDS dementia 
complex, and disseminated Mycobacterium avium complex) are defined based on 1993 criteria 
of the Centers of the Disease Control and Prevention75, and ascertained by the treating 
physicians. Dates of diagnoses of AIDS defining illnesses are recorded in the electronic medical 
record from each cohort. Serious non-AIDS events are defined as follows: cardiovascular disease 
(myocardial infarction, stroke, or coronary revascularization), end-stage renal disease (initiation 
of dialysis or renal transplantation), liver disease (decompensated liver disease), non–AIDS-
defining cancer (except for basal-cell or squamous-cell skin cancer).74 These endpoints are all 




cohort. Some cohorts have active endpoint adjudication in place, and non-adjudicated endpoints 
will be termed presumptive. Primary analysis will include both presumptive endpoints and those 
confirmed by adjudication. The date of death from any cause is identified from queries to the US 
Social Security Death Index and/or National Death Index. HIV RNA viral loads and CD4+ cell 
counts are measured using laboratory tests at study visits. 
 
Covariates 
Covariates include time-fixed and time-varying variables. Time-fixed covariates, 
measured at the start of follow-up (i.e., treatment initiation), are sex, race/ethnicity, age, history 
of male sex with men, history of injection drug use, smoking, BMI, diagnosis of depression or 
anxiety, baseline and nadir CD4+ cell count, baseline and peak HIV RNA viral load, cohort, 
calendar year, years since HIV diagnosis, and clinical diseases (e.g., hepatitis B and C virus 
infection, liver disease, diabetes mellitus, hypertension, cardiovascular and cerebrovascular 
diseases). Demographic variables including sex, age, race/ethnicity, history of male same sex 
activity and history of injection drug use are measured at baseline intake questionnaires. History 
of depression or anxiety diagnosis are typically recorded in the electronic medical record. 
Missing information on important covariates including race/ethnicity, injection drug use, and 
baseline CD4 cell count will be imputed 50 times allowing for nonmonotone missing data.76 
Time-varying covariates, used to account for possible bias due to informative dropout 
and treatment changes or switches, include CD4+ cell count, HIV RNA viral load, time since last 
laboratory measure, and diagnoses of clinical diseases (e.g., HCV, HBV, diabetes, and 




results obtained at baseline and at each visit during follow-up. In addition, dates of any regimen 
switches and changes are recorded in the electronic medical record.  
 
3.5 Analysis plans 
AIM 1: To examine the effect of InSTI-based HIV treatment regimens on biomarker outcomes. 
Aim 1 will examine whether InSTI-based regimens cause more rapid viral suppression 
and more favorable changes in CD4+ cell count compared with the EFV-based regimen. The 
time zero for analyses, or study origin, is treatment initiation date. We will categorize data into 
3-month intervals to accommodate discrepancy of timelines by different cohorts. Patients will be 
considered lost (i.e., dropouts) after 18 months without contact. The main study endpoint in this 
aim is achievement of a suppressed HIV RNA, i.e. an HIV concentration <200 copies/mL.  
First, we will build inverse probability of treatment initiation weights77 by examining the 
pretreatment covariates that influence the decision to initiate InSTI-based HIV treatment 
regimens rather than the EFV-based regimen. We group factors into 5 categories: 1) 
demographic factors including age, gender (including transgender), race (white, black, Asian, 
and other), and ethnicity (Hispanic or not); 2) behavioral factors including injection drug use, 
men who have sex with men, heterosexual behavior; 3) clinical factors including baseline HIV 
viral load (copies/ml) and CD4+ count (cells/µl), history of depression diagnosis, hepatitis B and 
C virus infection, liver disease, diabetes mellitus, hypertension, cardiovascular and 
cerebrovascular diseases; 4) other factors, e.g., year starting initial regimen. 
The primary analysis is the observational analog of an intention-to-treat analysis. We will 
estimate logistic models to predict uptake of InSTI versus the EFV-based regimen conditioning 




difference (and 95% confidence intervals) of achieving viral suppression comparing InSTI-based 
regimens with the EFV-based regimen at different follow-up times (i.e., 1 years, 3 years, and 7 
years).  
For the observational analog of the per-protocol effect, we will additionally censor 
patients with changes in treatment regimens.78,79 Treatment changes in both groups include 
treatment cessation and treatment switches. Treatment regimen changes that are considered 
allowable exceptions are a change from one InSTI regimen to another InSTI regimen (for 
instance, from a RAL-based regimen to a DTG-based regimen), and a change from the EFV-
based regimen to a NNRTI-based regimen of rilpivirine, TDF and FTC. Inverse probability of 
treatment and censoring weights will be combined with additional weights for treatment changes.  
Assuming no unmeasured confounding, we are able to consistently estimate the 
observational per-protocol risk differences for achieving viral suppression comparing InSTI-
based regimens with the EFV-based regimen.  
 
AIM 2: To evaluate the comparative effectiveness of InSTI-based HIV treatment regimens on 
long-term clinical endpoints over an EFV-based regimen.  
Aim 2 will examine the effect of InSTI-based treatment regimen on long-term clinical 
endpoints (AIDS-defining illnesses, serious non-AIDS events and all-cause mortality). Similar to 
Aim 1, the time origin is initiation of treatment. The primary analysis is again an observational 
analog of intention-to-treat effect. We will employ inverse probability weighting to account for 
potential confounding and informative dropout. We will estimate the 7-year risks, risk 
difference, and risk ratios, as well as 95% confidence intervals. We will explore the effect of 




endpoint (i.e., AIDS incidence, incidence of serious non-AIDS events, and all-cause mortality, 
using methods appropriate for competing risks.80,81 
For the observational analog of the per-protocol effect, we will additionally censor people 
with any change in treatment regimen. Exceptions to treatment regimen changes are the same as 
provided for Aim 1 above.  
 
3.6 Statistical power 
In the preliminary analysis of CNICS data comparing RAL-based to EFV-based regimens 
by Cole et al54, 415 (14%) of 3061 participants initiated the RAL-based regimens at study entry. 
The 4-year risk of incident AIDS or death among those initiating EFV-based regimens was 6.5%. 
Considering that the risk curves decelerated over follow-up, we estimate that the 8-year crude 
risk among those initiating EFV-based regimens is 12% (= 𝟔. 𝟓% ×
𝟏𝟎−(𝟏𝟎−𝟒)/𝟐
𝟒
). (Of course, 
this is an underestimate because we will also have serious non-AIDS events in the proposed 
study.) We also estimate conservatively that, based on our previous experience, the sample size 
in this proposal using NA-ACCORD data is about 3 times that of the CNICS sample. That is, 
about 9000 participants who initiated EFV-based or InSTI-based regimens will be included in 
this study.  
Although methods have not been developed to calculate statistical power of the inverse-
probability weighted estimator directly, we can extend a standard normal approximation for the 
statistical power for the difference in two binomials to account for variance inflation due to 
inverse probability weights.82 Specifically, the statistical power is determined in terms of the 















𝒑𝒋, 𝒏𝒋 represent the proportion and size of reference and treatment samples respectively denoted 
as 𝒋 = 𝟎, 𝟏, ?̅? is average 𝒑𝒋, and 𝜽 is the variance inflation factor. 
Based on our prior published works54, we estimate conservatively that the variance 
inflation factor will be 2. Then, combined with the expected sample size, the proportion of the 
study size initiating InSTI-based regimens (14%), and the estimated 10-year risk (12%) among 
those initiating the EFV-based regimen, the statistical power is shown in Figure 3.2 for different 
samples sizes and risk differences. With an 8-year risk difference of 4% comparing the EFV-
based regimen to InSTI-based regimens (i.e., risk is 12% for those initiating the EFV-based 
regimen, and 8% for those initiating InSTI-based regimens), the statistical power is 86% for a 
sample size of 9000.  
 
3.7 Interpretation of results 
If we see long-term benefits and fewer side effects and discontinuations of the InSTI-
based regimens over, or we see no differences with (as reported previously in limited data) the 
EFV regimen, then we add assurance to current guidelines, and provide evidence of continued 
spread of InSTIs. Contra wise, if we see negative long-term clinical outcomes on InSTI-based 
regimes this calls into question the advantages of InSTI-based regimens and current guidelines, 
and calls for speeding the development of new ART. Given the large sample size, rich covariate 
set, and thorough analyses, we will have impactful results based on new knowledge regardless of 
whether we find InSTI-based regimens to perform better, the same, or worse than the well-













Figure 3.1: The North American AIDS Cohort Collaboration of Research and 
























Figure 3.2: Statistical power based on risk difference comparing EFV-








CHAPTER 4: VIROLOGIC OUTCOMES AMONG ADULTS WITH HIV USING 
INTEGRASE STRAND TRANSFER INHIBITOR BASED ANTIRETROVIRAL 




Modern antiretroviral therapy (ART) is highly effective in suppressing plasma viremia 
(i.e., HIV RNA viral load),1 which is a central biomarker for HIV prognosis. Integrase strand 
transfer inhibitors (InSTI)-based regimens have been recommended as first-line ART for 
adults.2–4 Randomized trials have demonstrated that patients initiating InSTI-based regimens 
experienced more rapid control of plasma viremia, as well as better tolerability, compared with 
those initiating other regimens.5–13 However, published trials had limited follow-up periods (48 
weeks).5,10,14 Randomized evidence of long-term effectiveness of InSTI-based regimens 
remains unavailable.  
Here using observational data from a large collaboration of North American cohort 
studies, we estimate the effect of InSTI-based regimens, compared to an efavirenz (EFV)-based 
regimen, on plasma viremia over 7 years. 
 
 4.2 Methods 
Study Design  
The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) is the largest multisite collaboration of clinical and interval HIV cohorts in the 




Briefly, the NA-ACCORD consists of >20 cohorts and 200 clinical care sites that prospectively 
collect data on more than 180,000 adults living with HIV. Cohorts securely transfer 
demographic, medication, laboratory, diagnostic, and vital status data annually to the central 
Data Management Core (University of Washington, Seattle, WA, USA), where the data undergo 
quality control and are harmonized across cohorts for analyses by the Epidemiology/Biostatistics 
Core (Johns Hopkins University, Baltimore, MD, USA). The human subjects research activities 
of the NA-ACCORD and each participating cohort have been approved by their respective local 
Institutional review boards, the Johns Hopkins School of Medicine, and the University of North 
Carolina School of Medicine.  
 
Study Population and Eligibility Criteria 
In the present study, we included HIV-seropositive and ART-naïve adults (≥18 years) 
who initiated an ART regimen consisting of two nucleoside reverse transcriptase inhibitors (i.e., 
tenofovir disoproxil fumarate [TDF] or tenofovir alafenamide [TAF], and emtricitabine [FTC]) 
and either InSTI (i.e., raltegravir [RAL], dolutegravir [DTG], elvitegravir/cobicstat 
[EVG/COBI]) or EFV while under follow-up between July 2009 and December 2016 from 16 
clinic cohorts in the NA-ACCORD. The follow-up began in 2009, rather than 2007 when RAL 
was first approved by the FDA, because RAL was recommended only for those with drug 
resistance from 2007 to 2009. Patients excluded were: 1) those having prior ART experience; 2) 
those with baseline HIV viral suppression (HIV RNA viral load <200 copies/mL) that is 
measured within 90 days before to 7 days after ART initiation; 3) those without any 






The primary outcome was the repeated measurements of being virally suppressed (HIV 
RNA viral load <200 copies/mL vs. ≥200 copies/mL) since ART initiation. The timing and 
frequency of observed laboratory measurements for HIV RNA viral load since ART initiation 
varied by person. To standardize, we constructed time-updated HIV RNA viral load at 3-month 
intervals. If there were multiple HIV RNA measurements within a 3-month interval, an average 
of these measurements was adopted. 
 
Covariates 
We selected baseline covariates which we considered to be potential confounders for 
effect of ART initiation on the virologic outcome. Age, sex, race, ethnicity, and HIV-acquisition 
risk group (men who have sex with men, individuals reporting current or previous injection drug 
use, heterosexual behavior, and other) were self-reported at enrolment into the NA-ACCORD. 
History of any clinical AIDS diagnosis, hepatitis C infection (having a positive antibody test, or 
a detectable RNA, or the presence of hepatitis C genotype test), hepatitis B infection (defined as 
positive surface antigen test, a positive e-antigen test, or a positive DNA test result), depression, 
anxiety, diabetes mellitus (a glycosylated hemoglobin ≥6.5%, diabetes-specific medication, or a 
diagnosis with a diabetes-related medication), hypertension (clinical diagnosis and prescription 
of anti-hypertensive medication), elevated total cholesterol (≥240 mg/dL) were recorded at ART 
initiation. Body mass index, which was captured as the closest date to ART initiation, was 
calculated as weight (kilograms) divided by height (meters) squared. Baseline CD4 cell count 
(cells/μL) and HIV RNA viral load (copies/mL) were captured at the closest date to ART 




initiation and individual cohorts were captured as indicator variables. Restricted quadratic splines 
with four knots at 5th, 35th, 65th, and 95th percentiles were used to model continuous covariates 
including age, body mass index, CD4 cell count and HIV RNA viral load.84  
Time-varying covariates, which were used to account for ART treatment changes, 
included time-updated CD4 cell count, new occurrences of clinical diseases or conditions (i.e., 




We restricted analyses to apparent new users of ART to avoid selection bias due to the inclusion 
of prevalent users, and to mimic a randomized trial where treatment-naïve patients were 
randomly assigned to either the InSTI-based regimen or the active comparator EFV-based 
regimen.72 Each participant was followed from date of ART initiation (study entry for 
individuals and time origin for our study design) until the date of the last HIV RNA 
measurement or administrative end of follow-up (at 7 years, or 31 December 2016).  
Missing baseline covariates (see Table 4.1) were imputed 20 times using multiple 
imputation by chained equations.85,86 The imputation model included all baseline covariates, 
treatment regimen variable, and the repeatedly measured outcomes for HIV RNA viral load.87 
Baseline CD4 cell count and repeatedly measured HIV viral load were log-transformed to avoid 
negative imputed values. Of note, missing measurements of HIV RNA viral load were also 
imputed.  
For primary analyses, we estimated the observational analog of intention-to-treat effect of 




outcome (being virally suppressed or not) regardless of ART treatment changes. For intention-to-
treat analysis, in each imputed dataset, inverse probability of treatment weights were constructed 
to account for potential baseline confounding. These weights were assigned to each participant to 
create the intention-to-treat population, and then applied to repeated observed measures of being 
HIV virally suppressed or not within each participant. Using the weighted observed measures of 
being HIV virally suppressed or not, we then calculated the proportion virally suppressed over 
follow-up by treatment groups in the intention-to-treat population. For intention-to-treat effect, 
we estimated the difference in the proportion virally suppressed in the InSTI-based regimen, 
versus the EFV-based regimen, at 0.25, 0.5, 0.75, 1, 3, 5, 7 years since ART initiation. The 
standard error for these differences was estimated from a nonparametric bootstrap with 200 
random samples of participants with replacement for each imputed dataset.88 Rubin’s rule was 
applied to pool the results across imputed datasets to obtain the pooled differences with 95% 
confidence intervals (CIs).  
We also estimated the per-protocol effect of initiating and remaining on an InSTI-based 
regimen compared with initiating and remaining on the EFV-based regimen on the virologic 
outcomes.73,89 For per-protocol analysis, participants were additionally censored when they 
deviated from their initial treatment strategy (i.e., ART treatment changes). ART treatment 
changes were those with ART treatment discontinuations and switches. Exceptions from ART 
treatment changes included: 1) a change from one InSTI-based regimen to another InSTI-based 
regimen (for instance, from a RAL-based regimen to a DTG-based regimen); 2) a change from 
the EFV-based regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
regimen of rilpivirine, TDF and FTC; and 3) switch between TDF and TAF. We then constructed 




covariates to account for treatment changes over follow-up.78,90 These censoring weights were 
combined with inverse probability of treatment weights, assigned to each participant to create the 
per-protocol population, and then applied to repeated observed measures of being HIV virally 
suppressed or not within each participant. Using the weighted observed measures of being HIV 
virally suppressed or not, we then calculated the proportion virally suppressed over follow-up by 
treatment groups in the per-protocol population. For the per-protocol effect, we also estimated 
the difference in proportions virally suppressed for initiating and remaining on an InSTI-based 
regimen versus initiating and remaining on the EFV-based regimen at 0.25, 0.5, 0.75, 1, 3, 5, 7 
years since ART initiation. 
In secondary analyses, we applied the inverse probability of treatment and censoring 
weights to both observed and imputed measures of being HIV virally suppressed or not, and 
estimated the difference in proportions virally suppressed for intention-to-treat and per-protocol 
effects. 
SAS software version 9.4 (SAS Institute, Cary, North Carolina) was used for all analyses. 
 
4.3 Results 
A total of 15,318 participants in the NA-ACCORD were eligible and included in the 
study population. Among these participants, 5,519 (36.0%) initiated an InSTI-based regimen, 
and 9,799 (64.0%) initiated the EFV-based regimen between 2009 and 2016. Of 5,519 patients 
initiating an InSTI-based regimen, 1,783 (32.3%) initiated RAL, 3,137 (56.8%) initiated 
EVG/COB, and 599 (10.9%) initiated DTG. Secular trends of ART initiation in Figure 4.1 show 
an increased proportion of InSTI-based regimen initiators across calendar year from 2009 to 




4.2. Compared with those in the EFV group, the participants in the InSTI group were more likely 
to be female, report male-to-male sexual contact, and have a previous diagnosis of depression or 
anxiety. During the 7-year follow-up period, there were a total of 124,822 HIV viral load 
measurements recorded in the study population (34,781 in the InSTI group and 90,041 in the 
EFV group). The InSTI group had a median of 5 viral load measurements (interquartile range, 3–
8), and the EFV had a median of 9 viral load measurements (interquartile range, 5-13). The crude 
proportion virally suppressed among the study population is depicted in the upper panel of 
Figure 4.2. The proportion virally suppressed was 81.9% in the InSTI group, and 65.8% in the 
EFV group at 0.25 years after ART initiation, and then increased to 91.9% in the InSTI group 
and 92.3% in the EFV group at 7 years (shown in the upper panel of Figure 4.3).  
In the intention-to-treat analyses, after accounting for baseline confounding, the 
proportion virally suppressed is shown in the middle panel of Figure 4.2. The intention-to-treat 
differences in the proportion virally suppressed in the InSTI-based regimen versus the EFV-
based regimen, at 0.25, 0.5, 0.75, 1, 3, 5, 7 years since ART initiation are described in the middle 
panel of Figure 4.3. For example, at 0.25 years after ART initiation, the proportion virally 
suppressed was 81.3% in the InSTI group, and 67.3% in the EFV group, corresponding with a 
difference of 14.0% (95% CI: 12.4, 15.6). At 1 year after ART initiation, the proportion virally 
suppressed was 89.5% in the InSTI group and 90.2% in the EFV group, corresponding with a 
difference of -0.7% (95% CI: -2.1, 0.8). At 7 years after ART initiation, the proportion virally 
suppressed was 94.5% in the InSTI group, and 92.5% in the EFV group, corresponding with a 
difference of 2.0% (95% CI: -7.3, 11.3). 
 Sixty-eight percent of the participants initiating an InSTI-based regimen (3,750/5,519) 




change before the last measurement of HIV viral load or completing the study. In the per-
protocol analyses after accounting for baseline confounding and treatment changes, the model-
fitted proportion virally suppressed is shown in the lower panel of Figure 4.2. The per-protocol 
differences in the proportion virally suppressed in the InSTI-based regimen versus the EFV-
based regimen, at 0.25, 0.5, 0.75, 1, 3, 5, 7 years since ART initiation are described in the lower 
panel of Figure 4.3. At 0.25 years after ART initiation, the proportion virally suppressed was 
81.3% in the InSTI group, and 67.3% in the EFV group, corresponding with a difference of 
14.0% (95% CI: 8.7, 19.3). The proportion virally suppressed (comparing those in the InSTI 
group with those in the EFV group) became similar after 0.25 years. At 1 year after ART 
initiation, the proportion virally suppressed was 91.1% in the InSTI group, and 93.0% in the 
EFV group, corresponding with a difference of -1.8% (95% CI: -4.9, 1.3). At 7 years after ART 
initiation, the proportion virally suppressed was 100.0% in the InSTI group, and 92.5% in the 
EFV group, corresponding with a difference of 7.5% (95% CI: -0.3, 15.4). 
 The results of secondary analyses by including both the observed and imputed measures 
of being HIV virally suppressed were similar with the main analyses (see Figure 4.4). 
 
4.4 Discussion 
Using the observational data from this large collaboration of HIV cohorts in the United 
States and Canada over 7 years of follow-up, we found that InSTI-based regimens had more 
rapid virologic response compared with EFV-based regimens among adults living with HIV, 
especially during the first quarter (0.25 years) since ART initiation. However, both the intention-
to-treat and per-protocol analyses showed that, after 0.25 years since initiation, InSTI-based and 




analyses showed a potential virologic benefit of InSTI at year 7 since ART initiation, this 
estimate was diluted by the substantial uncertainty due to the smaller per-protocol sample that 
remained on the initial ART regimens at the end of the study. 
Our results, that patients initiating an InSTI-based regimen experienced more rapid 
virologic suppression than those initiating EFV-based regimens, align with the findings from 
prior randomized trials: STARTMRK (RAL vs. EFV)25, SINGLE (DTG vs. EFV)28, and Study 
102 (EVG vs. EFV)91. The STARTMRK trial showed a shorter time to achieve viral suppression 
for patients on raltegarvir than on efavirenz within 48 weeks after randomization. At 48 weeks, 
RAL-based regimen was found to be non-inferior to EFV-based regimen on viral suppression 
(86.1% vs. 81.9% of patients with a virologic response to treatment).25 At week 240, the study 
showed RAL induced significantly better viral suppression, though much of this difference could 
be explained by more treatment discontinuations among patients on efavirenz.92 In the SINGLE 
study that compared DTG plus abacavir/lamivudine (ABC/3TC) with the co-formulated 
EFV/FTC/TDF, at week 48, the proportion of being virally suppressed was higher in the 
DTG/ABC/3TC group than in the EFV/FTC/TDF group.28 The DTG/ABC/3TC group also had a 
shorter median time to viral suppression and lower rate of treatment discontinuations than the 
EFV/FTC/TDF group. The Study 102 trial, which compared co-formulated 
EVG/COBI/FTC/TDF versus co-formulated EFV/FTC/TDF, showed non-inferiority of the 
EVG-based regimen to the EFV-based regimen on viral suppression, and comparable number of 
treatment discontinuations.91  
Furthermore, our findings on virologic outcomes within 1 year after ART initiation were 
also consistent with the several existing observational studies.70,93 Edwards et al. used the data 




that patients initiating raltegravir spent more time alive and virally suppressed than those 
initiating efavirenz, which was primarily driven by more rapid viral response of raltegravir.70 
The probability of being alive and virally suppressed at 2.5 years was similar among these two 
regimens. In a retrospective single-center study of 155 treatment-naïve patients, Jacobson and 
Ogbuagu found patents on InSTI-based regimens experienced higher rates of virologic 
suppression within the 1 year after initiation, and shorter median time to viral suppression 
compared to patients on other ART regimens (including efavirenz).93  
Our study is subject to limitations. First, in the analysis of observational data, a key 
limitation is that the treatment was not randomly assigned. To achieve comparability of treatment 
groups all confounders must be measured with appropriate adjustments made. Although we 
adjusted for a large number of likely confounders, it is still possible that uncontrolled 
confounding remains. Second, while most published randomized trials used the definition of 
viral suppression as HIV RNA viral load <50 copies/mL, we chose to use the cutoff of HIV 
RNA <200 copies/mL as there were a portion of HIV viral load measurement with lower limit of 
detection greater than 50 copies/mL. Further, measurement error may occur during the 
measurement and classification of HIV viral suppression outcomes.  
In the present study, we used a large observational pooling project to replicate findings 
from randomized trials and extend the evidence base to a larger and more representative sample 
of adults living with HIV in the United States and Canada over a prolonged follow-up.94 We 
adopted a new-user study design and modern statistical and causal inference approaches to 
perform intention-to-treat and per-protocol analyses to mitigate concerns about baseline 
confounding and treatment discontinuations or switches, and provided comprehensive evidence 




In the present study, we used a large observational pooling project to replicate findings 
from randomized trials and the evidence base to a longer follow-up of 7-years, among a larger 
and more representative sample of treatment-naïve adults living with HIV in a real-world 
routine-care setting, which complements the findings from prior randomized trials and 
observational studies.94  We found that although InSTI-based regimens had more rapid response 
compared with efavirenz-based regimens, the long-term effect on virologic outcomes was similar 
for the InSTI-based regimens and efavirenz-based regimens. Our study also showed that the 
proportion of ART treatment changes including treatment switches and treatment 
discontinuations was high and comparable among patients initiating InSTI-based regimens and 
patients initiating efavirenz-based regimens, which contradicts the randomized evidence 
suggesting that InSTI-based regimens had fewer treatment discontinuations. Although the 
reasons for treatment changes were not captured in the NA-ACCORD, this discrepancy between 
clinical trials and our study might indicate the potential shortcomings of randomized trials that 
could not perfectly reflect the real-world settings. Combined with the increasing studies showing 
the potential adverse effects associated with InSTI, including neuropsychiatric toxicity64–66, 
neural tube defects36, weight gain59,61,95,96, and with our previous findings that there was no 
benefit of InSTI over efavirenz on clinical outcomes54, our results on a relatively similar long-
term virologic effect of InSTI bring into question whether InSTI-based regimens should be 
favored over other regimens, especially in the current context that dolutegravir-based regimens 





Table 4.1: Missing baseline covariates among 15,318 HIV-infected adults initiating an InSTI-
based regimen or an EFV-based regimen between July 2009 and December 2016 in the NA-
ACCORD, the United States and Canada 






 (n=5,519) (n=9,799) (n=15,318) 
Age 0 (0.0) 0 (0.0) 0 (0.0) 
Female 0 (0.0) 0 (0.0) 0 (0.0) 
Black race 123 (2.2) 300 (3.1) 423 (2.8) 
Hispanic ethnicity 123 (2.2) 300 (3.1) 423 (2.8) 
Body mass index 122 (2.2) 245 (2.5) 367 (2.4) 
Injection drug use 0 (0.0) 0 (0.0) 0 (0.0) 
Male-to-male sexual contact 0 (0.0) 0 (0.0) 0 (0.0) 
Heterosexual behavior 0 (0.0) 0 (0.0) 0 (0.0) 
Previous AIDS diagnosis 0 (0.0) 0 (0.0) 0 (0.0) 
Hepatitis B 20 (0.4) 27 (0.3) 47 (0.3) 
Hepatitis C 0 (0.0) 0 (0.0) 0 (0.0) 
Previous depression diagnosis 20 (0.4) 27 (0.3) 47 (0.3) 
Previous anxiety diagnosis  41 (0.7) 73 (0.7) 114 (0.7) 
Diabetes mellitus 1 (0.0) 0 (0.0) 1 (0.0) 
Hypertension 18 (0.3) 42 (0.4) 60 (0.4) 
Elevated total cholesterol 20 (0.4) 27 (0.3) 47 (0.3) 
Baseline CD4 countb  1,018 (18.4) 2,431 (24.8) 3,449 (22.5) 
Baseline viral loadc 1,171 (21.2) 2,813 (28.7) 3,984 (26.0) 
Calendar year at initiation 0 (0.0) 0 (0.0) 0 (0.0) 
Abbreviations: HIV, human immunodeficiency virus; InSTI, integrase strand transfer inhibitor; 
EFV, efavirenz; AIDS, acquired immunodeficiency syndrome 
a Both regimens included the same backbone of tenofovir disoproxil fumarate [or tenofovir 
alafenamide], and emtricitabine 
b Baseline CD4 count was captured at the closest date to ART initiation within the window from 
90 days before to 7 days after ART initiation 
c HIV viral load was captured at the closest date to ART initiation within the window from 90 






Table 4.2. Characteristics at ART initiation of 15,318 HIV-infected adults initiating an InSTI-
based regimen or an EFV-based regimen between July 2009 and December 2016 in the NA-
ACCORD, overall and by treatment regimens, the United States and Canada 






 (n=5,519) (n=9,799) (n=15,318) 
Age, median (IQR), yrs 38.0 (28.0-49.0) 41.0 (31.0-51.0) 
40.0 (30.0-
50.0) 
Female 836 (15.2) 1,055 (10.8) 1,891 (12.3) 
Black race 2,193 (39.7) 4,414 (45.1) 6,607 (43.1) 
Hispanic ethnicity 667 (12.1) 1,261 (12.9) 1,928 (12.6) 
Body mass index, median (IQR) 25.1 (22.3-28.7) 25.1 (22.4-28.6) 
25.1 (22.3-
28.6) 
Injection drug use 533 (9.7) 1,036 (10.6) 1,569 (10.2) 
Male-to-male sexual contact 3,036 (55.0) 4,343 (44.3) 7,379 (48.2) 
Heterosexual behavior 1,273 (23.1) 1,931 (19.7) 3,204 (20.9) 
Previous AIDS diagnosis 459 (8.3) 705 (7.2) 1,164 (7.6) 
Hepatitis B 206 (3.7) 404 (4.1) 610 (4.0) 
Hepatitis C 559 (10.1) 1,120 (11.4) 1,679 (11.0) 
Previous depression diagnosis 831 (15.1) 1,024 (10.5) 1,855 (12.1) 
Previous anxiety diagnosis 667 (12.1) 722 (7.4) 1,389 (9.1) 
Diabetes mellitus 276 (5.0) 555 (5.7) 831 (5.4) 
Hypertension 814 (14.8) 1,843 (18.8) 2,657 (17.4) 
Elevated total cholesterol 218 (4.0) 483 (4.9) 701 (4.6) 
Baseline CD4 count, median 


















Calendar year at initiation, median 





Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; InSTI, 
integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the North American AIDS 
Cohort Collaboration on Research and Design; IQR, interquartile range; AIDS, acquired 
immunodeficiency syndrome 
a Both regimens included the same backbone of tenofovir disoproxil fumarate [or tenofovir 





Figure 4.1. Secular trend in proportion of initiatiating InSTI- versus EFV-based regimens 
between July 2009 and December 2016 among 15,318 HIV-infected adults in the NA-ACCORD, 
the United States and Canada. Abbreviations: InSTI, integrase strand transfer inhibitor; EFV, 
efavirenz; NA-ACCORD, the North American AIDS Cohort Collaboration on Research and 






Figure 4.2. Proportion virally suppressed (<200 copies/mL) by ART group (InSTI- vs EFV-
based regimens) across 7-year follow-up among 15,318 HIV-infected adults in the NA-
ACCORD, the United States and Canada. The upper panel represents crude analyses, the middle 
panel represents intention-to-treat analyses that accounted for baseline confounding, and the 
lower panel represent per-protocol analyses that accounted for baseline confounding and ART 








Figure 4.3. Proportion difference (PD) virally suppressed (<200 copies/mL) comparing InSTI-
based regimen with EFV-based regimen across 7-year follow-up among 15,318 HIV-infected 
adults in the NA-ACCORD, the United States and Canada. The upper panel represents crude 
analyses, the middle panel represents intention-to-treat analyses that accounted for baseline 
confounding, and the lower panel represent per-protocol analyses that accounted for baseline 








Figure 4.4. Results of secondary analyses that showed proportion difference (PD) virally 
suppressed (<200 copies/mL) comparing InSTI-based regimen with EFV-based regimen across 
7-year follow-up among 15,318 HIV-infected adults in the NA-ACCORD, the United States and 
Canada. The upper panel represents crude analyses, the middle panel represents intention-to-treat 
analyses that accounted for baseline confounding, and the lower panel represent per-protocol 
analyses that accounted for baseline confounding and ART treatment changes (ART treatment 













CHAPTER 5: CLINICAL EFFECTIVENESS OF INTEGRASE STRAND TRANSFER 
INHIBITOR-BASED ANTIRETROVIRAL REGIMENS AMONG ADULTS WITH 
HUMAN IMMUNODEFICIENCY VIRUS 
 
5.1 Introduction 
Contemporary antiretroviral therapy (ART) is highly effective in suppressing plasma 
viremia and prolonging survival.11 Because there is no cure for human immunodeficiency virus 
(HIV), people living with HIV may be exposed to ART for decades97, and therefore, maximizing 
the safety profile and tolerability while maintaining strong potency remains a clinical priority. 
Integrase strand transfer inhibitor (InSTI)-based regimens are now recommended widely 
as first-line ART for adults.12,35,98 Randomized trials of InSTI-based regimens have demonstrated 
clear short-term evidence of strong potency as well as tolerability, compared with other 
regimens.25–29,32,33,91 However, most randomized trials have been focused on short-term (48 
weeks) surrogate biomarkers. Limited data are available regarding longer-term clinical 
effectiveness of InSTI-based regimens. The few existing observational studies that have 
examined the clinical effects and safety endpoints of InSTI-based regimens have one or more 
limitations, such as insufficient sample size and limited follow-up.54,69 We aimed to examine in a 
collaboration of cohort studies in the United States (U.S.) and Canada by emulating a 
randomized trial whether those initiating a regimen of InSTI with tenofovir disoproxil fumarate 
[TDF] or tenofovir alafenamide [TAF], and emtricitabine [FTC]) improved longer-term (6-year) 
clinical outcomes of AIDS-defining illnesses, all-cause mortality, and serious non-AIDS events 





 5.2 Methods 
Study Design  
The North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) is the largest consortium of clinical and interval HIV cohorts in North America and is 
one of the seven regional collaborations of the International Epidemiologic Databases to 
Evaluate AIDS (IeDEA) project, supported by the National Institutes of Health. Details on this 
collaboration have been published previously.83 Briefly, the NA-ACCORD consists of >20 
single-site and multisite cohorts that prospectively collect data on more than 180,000 adults 
living with HIV who had at least two care visits within 12 months at more than 200 clinical sites 
in the U.S. and Canada. Cohorts securely transfer demographic, medication, laboratory, 
diagnostic, and vital status data annually to the central Data Management Core (University of 
Washington, Seattle, WA, USA), where the data undergo quality control and are harmonized 
across cohorts for analyses by the Epidemiology/Biostatistics Core (Johns Hopkins University, 
Baltimore, MD, USA). The human subjects research activities of the NA-ACCORD and each 
participating cohort have been approved by their respective local Institutional review boards, the 
Johns Hopkins School of Medicine, and the University of North Carolina School of Medicine.  
 
Study Population and Eligibility Criteria 
This prospective cohort study included HIV-seropositive and ART-naïve adults aged 18 
years or older who initiated an ART regimen consisting of  TDF (or TAF), FTC, and either 
InSTI (i.e., raltegravir [RAL], dolutegravir [DTG], elvitegravir/cobicistat [EVG/COBI]) or EFV 




ACCORD.. We started follow-up in 2009, rather than 2007 when RAL was first approved by the 
FDA, because RAL was recommended only for those with drug resistance from 2007 through 
2009. Patients excluded were: 1) those having evidence of prior ART; 2) those with undetectable 
HIV RNA viral load measured within 90 days before to 7 days after ART initiation since 
undetectable viral load may indicate unreported or uncaptured treatment; 3) those having prior 
history of acute myocardial infarction (MI) or stroke, end-stage renal disease (ESRD) and end-
stage liver disease (ESLD). 
 
Outcome Assessment 
The primary outcome was a composite of the first occurrence of an AIDS-defining 
illness, a serious non-AIDS event, or death from any cause after ART initiation. AIDS-defining 
illnesses are based on 1993 criteria of the Centers of the Disease Control and Prevention (see 
Table 5.1 for specific AIDS-defining illnesses).75 Serious non-AIDS events were defined as 
follows: acute MI or stroke (based on diagnoses), ESRD (estimated glomerular filtration rate first 
consistently <30 mL/min per 1.73 m2 for at least 3 months with the second measurement date 
used for event), and ESLD (two FIB-4 [fibrosis-4] >3.25, more than 6 months apart with second 
measurement date used for event). ESRD and ESLD outcomes were based on laboratory tests as 
the date through which ESRD and ESLD events are validated in NA-ACCORD did not extend 
throughout the study follow-up. The diagnoses and laboratory tests were obtained from 
electronic medical records from each site. The date of death from any cause was identified from 
queries to the US Social Security Death Index, National Death Index, state (or provincial, for 






We selected baseline covariates which we considered to be potential confounders for 
effect of ART initiation on the composite outcome. Age, sex, race, ethnicity, and HIV-
acquisition risk group (men who have sex with men, individuals reporting current or previous 
injection drug use, heterosexual behavior, and other) were self-reported at enrolment into the 
NA-ACCORD. Body mass index and history of any clinical AIDS diagnosis, hepatitis C 
infection (having a positive antibody test, or a detectable RNA, or the presence of hepatitis C 
genotype test), hepatitis B infection (defined as positive surface antigen test, a positive e-antigen 
test, or a positive DNA test result), depression or anxiety diagnosis, diabetes mellitus (a 
glycosylated hemoglobin ≥6.5%, diabetes-specific medication, or a diagnosis with a diabetes-
related medication), hypertension (clinical diagnosis and prescription of anti-hypertensive 
medication), elevated total cholesterol (≥240 mg/dL), and statin prescription were recorded at 
ART initiation. Baseline CD4 cell count (cells/μL) and HIV viral load (copies/mL) were 
captured at the closest date to ART initiation within the window from 90 days before to 7 days 
after ART initiation. Calendar year at initiation was captured as indicator variables.  
Time-varying covariates, which were used to account for differential loss to follow-up 
and ART treatment changes, included time-updated CD4 cell count, HIV viral load, new 
occurrences of clinical diseases or conditions (i.e., diabetes mellitus, depression, anxiety, and 
hypertension), elevated total cholesterol, and new statin prescription after ART initiation.  
 
Statistical Analyses 
Our inclusion and exclusion criteria restricted our study population to those we believe 




selection bias due to the inclusion of prevalent ART users, and to mimic the setting of a 
randomized controlled trial where patients were randomly assigned to either the InSTI-based 
regimen or the active comparator EFV-based regimen through adjusting for baseline confounders 
measured in the NA-ACCORD.72  Each participant was followed from date of ART initiation 
(study entry for individuals and time origin for our study design) until the earliest date of first 
occurrence of the composite outcome, date of loss to follow-up (defined by NA-ACCORD as 18 
months after the date of last CD4 count or HIV viral load measurement), or administrative end of 
follow-up (at 6 years, cohort-specific end date, or 31 December 2016).  
Missing baseline covariates were imputed 10 times using multiple imputation by chained 
equations.85,86 (See Table 5.2 for proportion of missing values for each baseline covariate). The 
imputation model included all baseline covariates, treatment regimen variable, the binary 
outcome indicator, and the cumulative reference hazard.86 Baseline CD4 cell count and HIV viral 
load were log-transformed to avoid negative imputed values.  
For primary analyses, we estimated the observational analog of intention-to-treat effect of 
initiating an InSTI-based regimen compared with initiating the EFV-based regimen regardless of 
ART treatment changes. For intention-to-treat analysis, in each imputed dataset, we accounted 
for potential baseline confounding and differential loss to follow-up by constructing inverse 
probability of treatment weights and inverse probability of censoring weights, respectively. 
These weights were combined, and applied to Cox proportional hazard model for the composite 
outcome on initiating an InSTI-based regimen vs. initiating an EFV-based regimen. A robust 
standard error for hazard ratio was calculated for each imputed dataset. We also estimated the 6-
year intention-to-treat risk of the composite outcome for each treatment regimen and the 




Kaplan-Meier estimators.99,100 We estimated the 6-year risks because there were few patients in 
the InSTI group followed for more than 6 years since ART initiation. The standard error for risk 
difference was estimated from a nonparametric bootstrap with 200 random samples with 
replacement for each imputed dataset. Rubin’s rule was applied to pool the results across 
imputed datasets to obtain the pooled hazard ratio and 6-year risk difference with 95% 
confidence intervals (CIs).  
We also estimated the per-protocol effect of initiating and remaining on an InSTI-based 
regimen compared with initiating and remaining on the EFV-based regimen.73,89 For per-
protocol analysis, participants were additionally censored when they deviated from their initial 
treatment strategy (i.e., treatment changes). Treatment changes in both groups included treatment 
discontinuations and switches. Treatment changes that were considered allowable exceptions and 
thus were not censored were: 1) a change from one InSTI-based regimen to another InSTI-based 
regimen (for instance, from a RAL-based regimen to a DTG-based regimen); 2) a change from 
the EFV-based regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
regimen of rilpivirine, TDF and FTC; and 3) switch between TDF and TAF. The inverse 
probability of censoring weights were revised to censor at the minimum of loss to follow-up or 
treatment changes,78 and combined with inverse probability of treatment weights to estimate the 
6-year per-protocol risks, risk difference as well as hazard ratio.  
We assessed the robustness of our estimates using two secondary analyses: 1) we 
restricted the composite outcome only to the most HIV-relevant events – AIDS and death, as 
well as restricted to serious non-AIDS events; 2) we additionally adjusted for individual cohorts 
as a potential confounder; and 3) we reran the analyses stratified by baseline CD4 cell count 




SAS software version 9.4 (SAS Institute, Cary, North Carolina) was used for all analyses. 
 
5.3 Results 
Of 15,993 eligible participants in the NA-ACCORD, 5,824 (36.4%) initiated an InSTI-
based regimen, and 10,169 (63.6%) initiated the EFV-based regimen between 2009 and 2016. 
Among 5,824 patients initiating InSTI, 1,840 (31.6%) initiated RAL, 3,361 (57.7%) initiated 
EVG/COB, and 639 (10.7%) initiated DTG. Characteristics at initiation of the study population 
are described in Table 5.3. Compared to those in the EFV group, the participants in the InSTI 
group were more likely to be female, non-Black, report male-to-male sexual contact, and have a 
previous diagnosis of depression or anxiety. Secular trends showed an increased proportion of 
InSTI-based regimen initiators across calendar year from 2009 to 2016 (see Figure 5.1).  
During a median follow-up of 2.0 years (interquartile range [IQR] 1.2-3.2), 440 (7.6%) of 
the 5,824 participants who initiated an InSTI-based regimen incurred the composite outcome. 
Among these, 288 (5.0%) had an incident diagnosis of AIDS, 16 (0.3%) had a diagnosis of acute 
MI or stroke, 7 (0.1%) incurred end-stage renal disease, 40 (0.7%) incurred end-stage liver 
disease, and 89 (1.5%) died. Of the 10,169 participants initiating the EFV-based regimen with a 
median follow-up of 3.8 years (IQR 2.3-5.3), 1,097 (10.8%) experienced the composite outcome. 
Among these, 671 (6.6%) received a diagnosis of AIDS, 61 (0.6%) had a diagnosis of acute MI 
or stroke, 26 (0.3%) had end-stage renal disease, 116 (1.1%) incurred end-stage liver disease, 
223 (2.2%) died. A total of 3,104 (19.4%) among 15,993 participants were lost to follow-up with 
13.4% in an InSTI-based regimen (782/5,824) and 22.8% in the EFV-based regimen 
(2,322/10,169). Crude risk of loss to follow-up is shown in Figure 5.2. The 6-year risk of loss to 




After accounting for baseline confounding and differential loss to follow-up using inverse 
probability weighting, the intention-to-treat hazard ratio of the composite outcome comparing 
those who initiated an InSTI-based regimen with those who initiated the EFV-based regimen was 
1.08 (95% CI: 0.97, 1.19). The intention-to-treat 6-year risk of the composite outcome was 
14.6% among those initiating an InSTI-based regimen, and 14.3% among those initiating the 
EFV-based regimen, corresponding with a 6-year risk difference of 0.3 percentage point (95% 
CI: -2.7, 3.3) (Table 5.4). The Kaplan-Meier risk curve for adjusted intention-to-treat analyses 
across 6-year follow-up was depicted in the left panel of Figure 5.3.  
  Fifty-four percent of the participants initiating an InSTI-based regimen (3,140/5,824) and 
68% of the participants initiating the EFV-based regimen (6,964/10,169) had a treatment change 
before incurring the composite outcome, loss to follow-up or completing the study. Crude risk of 
treatment changes is shown in Figure 5.2. The 6-year risk of treatment change was 85.9% for the 
InSTI group, and 83.2% for the EFV group. After accounting for baseline confounding, 
differential loss-to-follow-up and treatment changes, the adjusted per-protocol hazard ratio of the 
composite outcome comparing those who initiated and remained on an InSTI-based regimen 
with those who initiated and remained on the EFV-based regimen was 1.09 (95% CI: 0.96, 1.25). 
The adjusted per-protocol 6-year risk of the composite outcome was 12.2% among those 
initiating and remaining on an InSTI-based regimen, and 11.9% among those initiating and 
remaining on the EFV-based regimen, corresponding with a 6-year risk difference was 0.3 
percentage point (95% CI: -3.0, 3.7) (Table 5.4). The Kaplan-Meier risk curve for adjusted per-




Effect estimates were similar under the secondary analyses for restricting to most relevant 
clinical events, restricting to serious non-AIDS events, including confounding by cohort, and 
stratifying by baseline CD4 cell count (see Table 5.5). 
 
5.4 Discussion 
Using this large collaboration of North American HIV cohorts, we found similar effects 
on a composite clinical outcome between InSTI-based and EFV-based initial antiretroviral 
therapy in both intention-to-treat and per-protocol analyses. This finding is consistent with 
previous literature54, but with a broader spectrum of clinical outcomes, longer follow-up, and 
larger sample size, these results provide more assurance of the safety and clinical effectiveness 
of the initiation of InSTI-based antiretroviral therapy. But they do not suggest that InSTI-based 
regimens have better clinical outcomes than the EFV-based regimen. Furthermore, our study 
showed that, in this sample with median age of 40 years, the 6-year risk of clinical outcomes was 
substantial for both InSTI and EFV groups (14% in intention-to-treat analyses and 12% in per-
protocol analyses).  
Existing randomized trials focused on short-term biomarkers suggested that patients 
initiating InSTI-based regimens experienced more rapid and potent antiretroviral activity, and 
fewer adverse events and drug interactions compared with those initiating other regimens.25–29,31–
33,91 Direct comparisons of efficacy and safety of InSTI-based regimens with EFV-based 
regimens have been performed in several randomized controlled trials: STARTMRK (RAL vs. 
EFV)25,37–40, SINGLE (DTG vs. EFV)28,41, and Study 102 (EVG vs. EFV)31,42,43,91. STARTMRK 
trial found non-inferiority of the RAL-based regimen to the EFV-based regimen on viral 




adverse events in the RAL group.25,37–40 At week 240, the study showed RAL induced 
significantly better viral suppression.92 In the SINGLE study directly comparing DTG plus 
abacavir/lamivudine (ABC/3TC) with the co-formulated EFV/FTC/TDF, DTG-based regimen 
was found to have a more favorable tolerability profile and lower rate of treatment 
discontinuations. 28,41 The Study 102 trial, which compared co-formulated EVG/COBI/FTC/TDF 
versus co-formulated EFV/FTC/TDF, showed a significantly better immunological recovery 
among the EVG group, but comparable rate of viral suppression and similar number of treatment 
discontinuations. 31,42,43,91 Overall, these trials suggested that InSTIs had a better virological 
response and tolerability with fewer treatment discontinuations, in contrast with our finding that 
InSTIs lead to a higher 6-year risk of treatment changes and had comparable long-term clinical 
effects with EFV. The discrepancies between clinical trials and real-world observational data 
may be due in part to the shorter duration of follow-up in clinical trials because some adverse 
effects may only occur after prolonged treatment exposure. Therefore, further research is 
warranted to incorporate and investigate the reasons for treatment changes, and provide 
additional insights on the tolerability of InSTI-based initial antiretroviral therapy in a real-world 
observational setting.  
Our study is subject to limitations. First, one key challenge in the analysis of 
observational data is that the treatment was not randomly assigned. That means, all baseline 
confounders should be measured and adjusted for to achieve comparability of treatment groups 
to emulate a randomized trial. It is possible that residual confounding was present. Second, 
ESRD and ESLD outcomes were based on laboratory tests. In addition, acute MI or stroke were 
based on diagnosis data because adjudicated events in NA-ACCORD were not available for all 




error. Future studies on validated outcomes including validated MI and cancer outcomes are a 
worthwhile addition. Third, we did not assess additional chronic disease outcomes or their 
proxies, such as weight gain or metabolic disorders, for which there is some evidence of 
enhanced risk when comparing InSTI-based to other regimens. Though there are currently both 
trial and observational data supporting the association of some InSTI-based regimens with more 
rapid weight gain59,61,95,96, and increases in waist circumference101, these may be intermediates of 
hard outcomes which we did assess in this analysis. We further felt that quantifying these 
relationships would be beyond the scope of this analysis and may merit separate study. Last, here 
we only estimated the overall clinical effects of InSTI class, and did not distinguish the clinical 
outcomes for each distinct InSTI agent because such detailed analyses would require a larger 
study.  
There are several strengths to our study that are worth noting. We used a large 
observational pooling project and emulated a randomized trial.94 First, the size, breadth, 
prolonged follow-up and representativeness of the NA-ACCORD data allowed us to more 
accurately quantify the clinical effect of InSTI-based initial antiretroviral therapy with 
adjustment for many potential confounders. Second, we restricted analyses to participants 
starting antiretroviral therapy so that prior use of ART could not bias the results.72 We also set 
time zero of our analyses to align with time zero of a randomized trial when eligibility criteria 
are met and treatment therapies were assigned. Further, we adopted modern causal and statistical 
approaches to perform intention-to-treat and per-protocol analyses to ameliorate the concern of 
baseline confounding, differential loss to follow-up, and treatment discontinuations and switches, 
which are difficult to address using traditional statistical methods, and provide comprehensive 




estimate the more patient-relevant measures of interest, such as absolute risks and risk 
differences, in addition to hazard ratios.  
In conclusion, employing a rigorous methodological approach, our study indicates a 
similar 6-year risk of composite clinical outcomes for initial InSTI-based regimens and the EFV-
based regimen by leveraging a large multisite observational cohort collaboration in the U.S. and 
Canada. Given the lack of existing or forthcoming longer-term randomized evidence, prospective 
cohort studies in real-world settings contribute to the evidence-base and supplement findings 
from randomized clinical trials. With principled causal and statistical methods, one can leverage 
observational data to obtain more accurate effect estimates, provide the best available evidence, 






Table 5.1. Incident type-specific AIDS-defining illnesses among 288 adults who initiated an 
InSTI-based regimen and incurred AIDS and 671 adults who initiated an EFV-based regimen 
and incurred AIDS as their first composite event between July 2009 and December 2016 in the 
NA-ACCORD, the United States and Canada 
First diagnosis of AIDS-defining illnesses after 





No. (%) No. (%) 
Candidiasis of bronchi, trachea, or lungs 0 (0.0) 0 (0.0) 
Candidiasis esophageal 27 (9.4) 55 (8.2) 
Candidiasis AIDS-defining unspecified  0 (0.0) 2 (0.3) 
Cervical cancer, invasive 5 (1.7) 6 (0.9) 
Coccidioidomycosis, disseminated or 
extrapulmonary 
0 (0.0) 5 (0.8) 
Cryptococcosis, extrapulmonary 15 (5.2) 26 (3.9) 
Cryptosporidiosis, chronic intestinal (greater 
than one month's duration) 
6 (2.1) 13 (1.9) 
Cytomegalovirus disease (other than liver, 
spleen or lymph nodes) 
2 (0.7) 3 (0.4) 
Cytomegalovirus retinitis (with loss of vision) 15 (5.2) 19 (2.8) 
Cytomegalovirus, not retinitis AIDS-defining 
unspecified  
2 (0.7) 2 (0.3) 
Cytomegalovirus, AIDS-defining unspecified 6 (2.8) 13 (1.9) 
Encephalopathy, HIV related 10 (3.5) 19 (2.8) 
Herpes simplex: chronic ulcer(s) (more than 1 
month in duration); or bronchitis, pneumonitis, 
or esophagitis 
30 (10.4) 34 (5.1) 
Histoplasmosis, disseminated or 
extrapulmonary 
5 (1.7) 7 (1.0) 
Isosporiasis, chronic intestinal (more than 1 
month in duration) 
0 (0.0) 0 (0.0) 
Kaposi sarcoma 23 (8.0) 80 (11.9) 
Non-Hodgkin’s Lymphoma, Burkitt's 9 (3.1) 10 (1.5) 
Non-Hodgkin’s Lymphoma, immunoblasti 2 (0.7) 0 (0.0) 
Non-Hodgkin’s Lymphoma, primary, of brain 1 (0.4) 3 (0.5) 
Non-Hodgkin’s Lymphoma, unspecified  13 (4.5) 35 (5.2) 
Mycobacterium avium complex or M kansasii, 
disseminated or extrapulmonary 
10 (3.5) 17 (2.5) 
Mycobacterium tuberculosis, any site 
(pulmonary or extrapulmonary) 
27 (9.4) 79 (11.8) 
Mycobacterium, other species or unidentified 
species, disseminated or extrapulmonary 
7 (2.4) 29 (4.3) 
Pneumocystis pneumonia (PCP) 33 (11.5) 106 (15.8) 
Pneumonia, recurrent 10 (3.5) 17 (2.5) 
Progressive multifocal leukoencephalopathy 4 (1.4) 5 (0.8) 




Toxoplasmosis of brain 6 (2.1) 13 (1.9) 
Wasting syndrome due to HIV 19 (6.6) 67 (10.0) 
Non-Hodgkin’s lymphoma, large cell 1 (0.4) 6 (0.9) 
Total 288 (100.0) 671 (100.0) 
Abbreviations: InSTI, integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the 
North American AIDS Cohort Collaboration on Research and Design 
a Both regimens included the same backbone of tenofovir disoproxil fumarate [or tenofovir 





Table 5.2. Missing baseline covariates among 15,993 HIV-infected adults initiating an InSTI-
based regimen or an EFV-based regimen between July 2009 and December 2016 in the NA-
ACCORD, the United States and Canada 






 (n=5,824) (n=10,169) (n=15,993) 
Age 0 (0.0) 0 (0.0) 0 (0.0) 
Female 0 (0.0) 0 (0.0) 0 (0.0) 
Black race 135 (2.3) 317 (3.1) 452 (2.8) 
Hispanic ethnicity 135 (2.3) 317 (3.1) 452 (2.8) 
Body mass index 143 (2.5) 273 (2.7) 416 (2.6) 
Injection drug use 0 (0.0) 0 (0.0) 0 (0.0) 
Male-to-male sexual contact 0 (0.0) 0 (0.0) 0 (0.0) 
Heterosexual behavior 0 (0.0) 0 (0.0) 0 (0.0) 
Previous AIDS diagnosis 0 (0.0) 0 (0.0) 0 (0.0) 
Hepatitis B 28 (0.5) 30 (0.3) 58 (0.4) 
Hepatitis C 0 (0.0) 0 (0.0) 0 (0.0) 
Previous depression diagnosis 30 (0.5) 31 (0.3) 61 (0.4) 
Previous anxiety diagnosis  52 (0.9) 78 (0.8) 130 (0.8) 
Diabetes mellitus 2 (0.0) 1 (0.0) 3 (0.0) 
Hypertension 25 (0.4) 42 (0.4) 67 (0.4) 
Statin prescription 25 (0.4) 27 (0.3) 52 (0.3) 
Elevated total cholesterol 28 (0.5) 30 (0.3) 58 (0.4) 
Baseline CD4 countb  1,034 (17.8) 2,425 (23.8) 3,459 (21.6) 
Baseline viral loadc 1,167 (20.0) 2,769 (27.2) 3,936 (24.6) 
Calendar year at initiation 0 (0.0) 0 (0.0) 0 (0.0) 
Abbreviations: HIV, human immunodeficiency virus; InSTI, integrase strand transfer inhibitor; 
EFV, efavirenz; AIDS, acquired immunodeficiency syndrome 
a Both regimens included the same backbone of tenofovir disoproxil fumarate [or tenofovir 
alafenamide], and emtricitabine 
b Baseline CD4 count was captured at the closest date to ART initiation within the window from 
90 days before to 7 days after ART initiation 
c HIV viral load was captured at the closest date to ART initiation within the window from 90 





Table 5.3. Characteristics at ART initiation of 15,993 HIV-infected adults initiating an InSTI-
based regimen or an EFV-based regimen between July 2009 and December 2016 in the NA-
ACCORD, overall and by treatment regimens, the United States and Canada 






 (n=5,824) (n=10,169) (n=15,993) 
Age, median (IQR), yrs 37.0 (28.0-48.0) 41.0 (31.0-50.0) 
40.0 (30.0-
50.0) 
Female 894 (15.3) 1,101 (10.8) 1,995 (12.5) 
Black race 2,351 (40.4) 4,611 (45.3) 6,962 (43.5) 
Hispanic ethnicity 722 (12.4) 1,350 (13.3) 2,072 (13.0) 
Body mass index, median (IQR) 25.1 (22.3-28.7) 25.1 (22.3-28.6) 
25.1 (22.3-
28.6) 
Injection drug use 566 (9.7) 1,033 (10.2) 1,599 (10.0) 
Male-to-male sexual contact 3,209 (55.1) 4,523 (44.5) 7,732 (48.4) 
Heterosexual behavior 1,349 (23.2) 2,030 (20.0) 3,379 (21.1) 
Previous AIDS diagnosis 480 (8.2) 735 (7.2) 1,215 (7.6) 
Hepatitis B 214 (3.7) 426 (4.2) 640 (4.0) 
Hepatitis C 564 (9.7) 1,123 (11.0) 1,687 (10.6) 
Previous depression diagnosis 859 (14.8) 1,038 (10.2) 1,897 (11.9) 
Previous anxiety diagnosis 692 (11.9) 727 (7.2) 1,419 (8.9) 
Diabetes mellitus 284 (4.9) 545 (5.4) 829 (5.2) 
Hypertension 817 (14.0) 1,792 (17.6) 2,609 (16.3) 
Statin prescription 340 (5.8) 806 (7.9) 1,146 (7.2) 
Elevated total cholesterol 224 (3.9) 508 (5.0) 732 (4.6) 
Baseline CD4 count, median 
















Calendar year at initiation, 





Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; InSTI, 
integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the North American AIDS 
Cohort Collaboration on Research and Design; IQR, interquartile range; AIDS, acquired 
immunodeficiency syndrome 
a Both regimens included the same backbone of tenofovir disoproxil fumarate [or tenofovir 




Table 5.4. Estimated 6-year risk differences and hazard ratios of the composite outcome 
comparing adults initiating an InSTI-based regimen with those initiating an EFV-based regimen 
between July 2009 and December 2016 in the NA-ACCORD, the United States and Canada 










(95% CI), % 
Hazard Ratio 
(95% CI) 
Crudeb        
    EFV 10,169 38029.3 1,097 14.2 0 1 
    InSTI 5,824 13240.8 440 13.1 -1.1 (-4.1 to 
1.9) 
0.99 (0.88 to 
1.10) 
Intention-to-treatc           
    EFV 10,169 38029.3 1,097 14.3 0 1 
    InSTI 5,824 13240.8 440 14.6 0.3 (-2.7 to 
3.3) 
1.08 (0.97 to 
1.19) 
Per-protocold           
    EFV 10,169 25100.8 672 11.9 0 1 
    InSTI 5,824 9313.0 325 12.2 0.3 (-3.0 to 
3.7) 
1.09 (0.96 to 
1.25) 
Abbreviations: InSTI, integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the 
North American AIDS Cohort Collaboration on Research and Design; CI, confidence interval 
a Composite outcome included AIDS-defining illnesses, acute myocardial infarction or stroke, 
end-stage renal diseases, end-stage liver diseases, or death 
b Crude analysis did not account for baseline confounding, different loss to follow-up and 
treatment changes (uncensored). 
c Intention-to-treat analyses accounted for baseline confounding and differential loss to follow-up 
d Per-protocol analyses accounted for baseline confounding, differential loss to follow-up, and 





Table 5.5. Secondary analyses for the effect on composite outcome comparing adults initiating 
an InSTI-based regimen with those initiating an EFV-based regimen between July 2009 and 
December 2016 in the NA-ACCORD, the United States and Canada 
 6-year Risk Difference (95% 
CI), % 
Hazard Ratio (95% CI) 
Secondary analysis 1 a   
    AIDS and death   
       Intention-to-treat b -0.4 (-3.8 to 3.0) 1.07 (0.96 to 1.20) 
       Per-protocol c 0.9 (-2.7 to 4.6) 1.12 (0.98 to 1.29) 
  Serious non-AIDS events   
       Intention-to-treat  0.9 (-5.1 to 6.9) 1.16 (0.92 to 1.47) 
       Per-protocol  0.2 (-7.3 to 8.0) 1.29 (0.96 to 1.73) 
Secondary analysis 2 d   
       Intention-to-treat 0.2 (-2.5 to 3.0) 1.06 (0.96 to 1.18) 
       Per-protocol 1.1 (-2.3 to 4.6) 1.12 (0.98 to 1.27) 
Secondary analysis 3   
  CD4 cell count ≤200 
cells/μL       
  
       Intention-to-treat 2.1 (-3.4 to 7.6) 0.96 (0.81 to 1.13) 
       Per-protocol  0.4 (-6.0 to 6.9) 0.99 (0.81 to 1.22) 
  CD4 cell count >200 
cells/μL 
  
       Intention-to-treat 1.1 (-2.2 to 4.4) 1.22 (0.99 to 1.50) 
       Per-protocol  0.0 (-3.8 to 3.8) 1.20 (0.96 to 1.51) 
Abbreviations: InSTI, integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the 
North American AIDS Cohort Collaboration on Research and Design; CI, confidence interval. 
a In secondary analysis 1, we restricted the composite outcome only to AIDS or death 
b Intention-to-treat analyses accounted for baseline confounding and differential loss-to-follow-
up. We compared the InSTI group to the EFV group for the effect estimate  
c Per-protocol analyses accounted for baseline confounding, differential loss-to-follow-up, and 
treatment changes (i.e., treatment discontinuations or switches). We compared the InSTI group 
to the EFV group for the effect estimate 






Figure 5.1. Secular trend in initiation of InSTI- versus EFV-based regimens between July 2009 
and December 2016 in the NA-ACCORD, the United States and Canada. Abbreviations: InSTI, 
integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the North American AIDS 







Figure 5.2. Crude risks of loss-to-follow-up and treatment changes during 6-year follow-up 
period among 15,993 HIV-infected adults initiating an InSTI-based regimen or an EFV-based 
regimen between July 2009 and December 2016 in the NA-ACCORD. Composite events were 
censored. Treatment changes that were considered allowable exceptions and thus were not 
included in this analysis were: 1) a change from one InSTI-based regimen to another InSTI-
based regimen (for instance, from a RAL-based regimen to a DTG-based regimen); 2) a change 
from the EFV-based regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based 
regimen of rilpivirine, TDF and FTC; and 3) switch between TDF and TAF.Abbreviations: 
InSTI, integrase strand transfer inhibitor; EFV, efavirenz; NA-ACCORD, the North American 
AIDS Cohort Collaboration on Research and Design; ART, antiretroviral therapy.  
 







                                                                                                                                                                                                                                                                                                                                                                                                          
Figure 5.3. Risk of the composite outcome (AIDS-defining illnesses, acute myocardial infarction 
or stroke, end-stage renal diseases, end-stage liver diseases, or death) among 15,993 HIV-
infected adults initiating an InSTI-based regimen or an EFV-based regimen between July 2009 
and December 2016 in the NA-ACCORD. The left panel represent intention-to-treat analyses 
that accounted for baseline confounding and differential loss-to-follow-up, and the right panel 
represent per-protocol analyses that accounted for baseline confounding, differential loss to 









CHAPTER 6: CONCLUSION 
 
6.1 Overview 
 New InSTI-based regimens have been recommended as first-line antiretroviral therapy 
(ART) for adults with human immunodeficiency virus. But evidence on long-term clinical 
effectiveness of InSTI-based regimens remains limited. In this work, we explored the long-term 
effects of InSTI on virologic and clinical outcomes using the large pooled observational data. We 
used data from the prospective cohort HIV collaboration to emulate a randomized trial through a 
sophisticated study design, and estimated observational analogs of both the intention-to-treat and 
per-protocol effects to add needed information to the evidence base about the long-term 
comparative effectiveness of InSTI-based regimens. 
 In Aim 1, we estimated the consecutive proportions virally suppressed among those who 
initiated the InSTI-based regimens and those who initiated the EFV-based regimens across 7-
year follow-up period. These estimates were aimed to first replicate and then extend the results 
of randomized trials, and examine if InSTI-based regimens have a better viral response compared 
with EFV-based regimens. The results may be of particular interest to clinical trialists and 
clinicians, and give them a sense how observational data can be used to replicate and extend 
randomized evidence.  
 The results from Aim 2 are particularly important from the patient-centered perspective. 
The HIV randomized trials are primarily focused on the surrogate biomarkers including CD4 cell 




the clinical effects of these ART drugs. Although InSTI-based regimens have been 
recommended as first-line ART treatment, this knowledge gap about the clinical effectiveness of 
InSTI has not been adequately addressed in existing research. We used pooled data from HIV 
cohort studies in the United States and Canada, and employed new epidemiology study designs, 
coupled with causal and statistical inference methods to assess the impact of InSTI-based 
regimens on clinical outcomes including AIDS-defining illnesses, serious non-AIDS events and 
all-cause mortality over prolonged follow-up. 
 
6.2 Study findings 
 In Chapter 4, we estimated the effects of InSTI-based regimens on viral suppression over 
7-years of follow-up. We found that initiating InSTI-based regimens led to more rapid decline in 
HIV viral load than initiating EFV-based regimens among adults living with HIV, especially 
during the first quarter (0.25 years) since ART initiation, which aligns with the results of 
randomized trials that compared the InSTI-class drug (i.e., RAL, EVG, DTG) with EFV. 
However, both the intention-to-treat and per-protocol analyses showed that InSTI-based and 
EFV-based regimens showed similar longer-term (7-year) effects on viral suppression. To our 
knowledge, this is the first study to have examined the virologic effect of InSTI with such a long 
follow-up duration. The most relevant study has shown similar results over a 2.5-year follow-
up.102 
 In Chapter 5, we estimated the effects of InSTI-based regimens on clinical outcomes 
including AIDS, death, and serious non-AIDS events over 6-years of follow-up. Similar to Aim 
1, we used observational data to mimic a randomized trial, and estimated the observational 




that examined the effects of InSTI on a broad spectrum of clinical outcomes over such prolonged 
follow-up. As a result, we found that InSTI-based and EFV-based initial ART regimens had 
similar 6-year effects on the composite clinical outcome including AIDS-defining illnesses, 
serious non-AIDS events, and death. These results contradicted our prior expectation or 
hypothesis that the newer class InSTI should have a more favorable clinical profile compared 
with EFV. As randomized trials are mainly focused on short-term surrogate biomarkers, our 
results raise the question whether current HIV randomized trials are sufficient to provide a strong 
evidence base on the effectiveness of HIV drugs, and whether and how policy makers might use 
both randomized and observational evidence for improved decision making. With advances in 
statistical methods and increased availability of observational data, more research should be 
devoted to using observational data to estimate the clinical effectiveness of HIV ART drugs 
under the real-world settings.  
 In summary, our studies suggest although InSTI presented a more rapid viral potency 
compared with EFV, the long-term effects of InSTI-based initial regimens on virologic and 
clinical outcomes were similar to EFV-based regimens. In addition, our data showed the 
increased popularity in initiating InSTI-based regimens compared with EFV-based regimens 
since 2009, as expected. However, what is unexpected is that both our studies have shown that 
patients that initiated InSTI-based regimens had a larger proportion of loss to follow-up and 
treatment changes (i.e., treatment switches and discontinuations) compared with those initiated 
EFV-based regimens, which contradicted the randomized evidence that showed InSTI-based 
regimens had fewer treatment discontinuations. This discrepancy may be because: 1) clinical 
trials have relatively shorter follow-up duration but some adverse effects may only occur after 




prolong follow-up; 2) the differences in study populations between the clinical trials and our 
observational study, as clinical trials often excluded a portion of sample due to strict eligibility 
criteria and monitored patients under more controlled settings, and our pooled observational data 
presented a broad, more heterogeneous population; 3) there were some prognostic factors for 
treatment discontinuations that we could not adjust for in our observational data; and 4) potential 
measurement error during the electronic medical recording for treatment switches and 
discontinuations in our observational studies. Overall, the main findings from our studies are that 
InSTI-based and EFV-based regimens have a similar long-term effects on virologic and clinical 
outcomes, which should be of strong interest to a broad party of stakeholders, including health 
providers, policy makers, patients and pharmaceutical companies, especially in the current 
context that the InSTI-class drug dolutegravir are being rolled out globally and extensive 
research is being conducted over InSTI for maintenance therapy and pre-exposure prophylaxis.  
 
6.3 Strengths  
 Our work resulted in a valuable addition to current literature. This work is the first and 
longest study that examined the long-term comparative effectiveness of InSTI-based regimens on 
comprehensive outcomes including viral suppression and a wide variety of clinical outcomes.  
 Our study used the large pooled HIV cohort collaboration (NA-ACCORD) to address our 
study aims. The NA-ACCORD presents a heterogeneous and representative population living 
with HIV in the United States and Canada, which enables us to generate directly applicable and 
policy-relevant effect estimates of InSTI among patients living with HIV under routine care 
beyond traditional randomized trials. The rich and broad sample allows us to more precisely 




addition, measurement of a multitude of covariates give us a unique opportunity to adjust for 
many important confounders and thereby estimate more accurate effects.  
 The new user design72 and sophisticated analytic approach for this work also add to its 
strength. We restricted analyses to participants initiating antiretroviral therapy so that prior use of 
ART could not bias the results, and this approach also allows us to mimic a randomized trial that 
compares InSTI-based regimens and EFV-based regimens. In addition, we identified the baseline 
covariate measurement at ART initiation, defined the eligibility criteria, and set time zero as the 
ART initiation, which align with the settings of randomized trials. Further, we adopted 
appropriate statistical approaches to perform the observational analogs of intention-to-treat and 
per-protocol analyses by adjusting for a multitude of baseline and time-varying covariates to 
mitigate the concern of baseline confounding, differential loss to follow-up, and treatment 
discontinuations and switches that could occur in the observational settings. These concerns 
could not be addressed using traditional statistical methods (e.g., straightforward Cox 
proportional hazard models). The observational analogs of intention-to-treat and per-protocol 
effects provide comprehensive clinical evidence about the effectiveness of InSTIs. Last, we used 
multiple imputation to impute the baseline missing covariates. Although missing, or “dark” data 
are always a concern, recently epidemiologists and statisticians have been concentrating attention 
of this issue.103 However, so-called complete-case analysis remains the main approach in 
epidemiologic studies, which could bias the results if the missingness is not completely at 
random. Using multiple imputation to impute the missing data enables us to generate more 
efficient and valid effect estimates, by relaxing our assumption to the data being missing at 






 Using observational data is well-suited and inescapable for our aims, in the absence of 
randomized evidence existing or forthcoming. However, our study is also subject to several 
limitations. First, a key limitation in the analysis of observational data is that the treatment was 
not randomly assigned. To achieve comparability of treatment groups all confounders must be 
measured and appropriate adjustments made. However, such assumptions are unverifiable using 
observational data. Although we adjusted for a large number of likely confounders, it is still 
possible that uncontrolled confounding remains. For example, education level is not recorded in 
the NA-ACCORD, and it may be a potential confounder for the effects of InSTI on clinical 
outcomes. Further, varying prescribing behaviors of ART drugs by different clinicians are not 
possible to be measured, but could potentially impact the effects of InSTI.  
 Second, our study may suffer from potential measurement error. In Aim 1, we chose to 
use the cutoff of HIV RNA <200 copies/mL instead of <50 copies/mL that was used in most 
published randomized trials, because in our study there were a portion of HIV viral load 
measurement with lower limit of detection greater than 50 copies/mL. Our choice may lead to 
potential misclassification and result in bias in our effects estimates. In Aim 2, some clinical 
outcomes including acute MI or stroke, ESRD, and ESLD are only based on laboratory tests and 
diagnosis, and are not fully adjudicated, which could result in possible outcome 
misclassification.  
 Third, apart from the comparability of treatment groups (known as exchangeability90) and 
no measurement error, identification of causal intention-to-treat and per-protocol effects also can 
be identified with following assumptions of treatment version irrelevance (namely, any versions 




observed for every combination of values of treatment and covariate histories for treatment 
models, and for every combination of values of censoring and covariate histories for censoring 
models)107, no interference between patients included in the study108, no measurement error and 
correct specification of statistical models (e.g., treatment, censoring). Most of these assumptions 
are untestable. Any violations of these assumptions could lead to biased estimates of our causal 
effects of InSTI. For example, as we included many baseline covariates and time-varying 
covariates for our treatment and censoring models, it is possible that positivity assumption is not 
met. Fortunately, the large sample size, and the somewhat haphazard nature of treatment and 
censoring, combine to mitigates this concern.  
Model specification may also be an issue, as we used parametric models to predict the 
probability of treatment and censoring. The parametric model assumptions are probably violated. 
However, by using flexible model techniques, such as quadratic splines terms for continuous 
covariates, we hope to well-approximate the underlying relationships. We also could not test the 
assumption of treatment version irrelevance. In our work, we only have the prescribing record of 
ART drugs from electronic medical records, and however, we do not have the available data on 
the true adherence from each patient. We are bolstered by the fact that both the InSTI- and EFV-
based regimens come in standard fixed-dose preparations. It is possible that we treat all patients 
on InSTI as simply taking InSTI, but different patients may have varying adherence patterns, 
which are unobserved but can lead to different levels of virologic and clinical severity. Future 
work is needed to explore this possibility. 
 Fourth, in both Aim 1 and Aim 2, we only estimated the overall effects of InSTI class, 
and did not estimate single components of each InSTI-class drug (i.e., RAL, EVG, DTG). We 




these 3 distinct InSTI-class drug. However, such detailed individual analyses would require a 
larger study, and the sets of covariates required to make the individual drugs exchangeable 
would be difficult to identify. 
 Fifth, in our per-protocol analyses, we censored all the treatment switches and 
discontinuations, as our observational data did not record the reasons for stopping or 
discontinuing the ART regimens. However, the per-protocol analyses usually do not censor when 
patients stop treatment due to clinically indicated toxicity because these treatment changes due to 
toxicity is often defined in the protocol specified prior to the study. Thus, our censoring approach 
may have some impact on the validity of the per-protocol effects. This assumption is testable 
only if we had additional data on reason for stopping or switching treatments. In addition, when 
dealing with per-protocol analyses in Aim 2, we censored patients at the minimum of loss to 
follow-up or treatment changes. Creating weights based on a combination of loss to follow-up 
and treatment changes assumes a common set of variables and association between loss to 
follow-up, treatment changes and the composite clinical outcome of interest. this assumption is 
verifiable, but only given enough data to estimate the parameters separately 
 Last, in our study, we only explored the effectiveness of InSTI-based regimens. We did 
not take into account the other features including the drug interactions, convenience, cost-
effectiveness and resistance mutations of the ART regimens. To better inform the HIV treatment 
guidelines and policy, our findings could be combined with other existing and forthcoming work 
on these features to provide a more comprehensive evidence base.  
 Even with these limitations, our work provides valuable evidence that adds to the existing 




decision and policy making. The novel study design along with sophisticated statistical methods 
employed make this work a powerful and important contributions to the HIV treatment literature.  
 
6.5 Future directions 
 We have examined the long-term effects of InSTI-based initial regimens on virologic and 
clinical outcomes. However, as demonstrated in the limitations, in Aim 2, some components of 
the composite outcome (e.g., acute MI or stroke) were not adjudicated, and thus may suffer from 
measurement error. In addition, cancer outcomes, as an important endpoint, were not included 
because they were not fully validated during the analysis phase. Thus, future work could be 
aimed to examine the effect of InSTI-based regimens on validated outcomes including MI and 
cancer, which is a worthwhile addition to our work. 
 Second, as follow-up duration is prolonged and sample size on those initiating InSTI-
based regimens increase, future studies are warranted to explore the clinical effects of individual 
InSTI-based regimen. Each individual InSTI drugs may have different advantages and 
disadvantages, in terms of either the clinical effectiveness or other aspects such as cost, 
convenience, and resistance mutations. Thus, results from such individual detailed analyses can 
provide more informative perspectives for patients, clinicians and policy makers.  
 Third, cost-effectiveness research of the InSTI-based regimen is necessary to better 
inform HIV treatment guidelines and policy-making, especially in the resource limited setting. 
Incorporating cost-effectiveness into our effect estimates will aid policy making by 1) providing 
estimates relevant in a resource-constrained setting, especially in the developing world and 




regimens, and 2) providing evidence that could be used in negotiations with pharmaceutical 
manufacturers.  
 Fourth, our work shows that patients that initiated the InSTI-based regimens had higher 
proportion of loss to follow-up and treatment changes compared with those that initiated the 
EFV-based regimen, which contradicted the findings from randomized trials. However, the 
reasons that caused such discrepancy have not been fully explored. Future work should be 
devoted to incorporating and investigating the reasons for treatment changes, and providing 
deeper insights on the tolerability of InSTI-based initial antiretroviral therapy in a real-world 
observational setting. 
 Last, future studies should also focus on other newly-developed InSTI-class drugs 
including bictegravir and cabotegravir, which have not been examined in the current work. These 
newly developed InSTI-class drugs have received increasing attention due to their potency and 
convenience. Assessment of long-term clinical effectiveness of these promising new drugs will 
also be necessary.  
 
6.6 Public health significance and conclusion of our work 
From the substantive perspective on HIV treatment, our studies showed that although 
InSTI-based initial ART regimens had a more rapid viral response compared with the EFV-based 
initial ART regimen, the long-term effects on virologic and clinical outcomes were similar. 
Along with the increasing studies showing the potential adverse effects associated with InSTI 
including neuropsychiatric toxicity64–66, neural tube defects36, weight gain59,61,95,96,  our results on 




be favored over other regimens, especially in the current context that dolutegravir-based 
regimens are being rolled-out globally. 
From the methodologic perspective, our work demonstrates that, in the absence existing 
or forthcoming longer-term randomized evidence, observational data in real-world settings can 
be used to replicate, extend, and complement findings from randomized clinical trials, and 
contribute to the evidence base. Using principled methods for causal and statistical inference, 
one can leverage observational data to obtain more accurate effect estimates, providing the best 
available evidence, and directly address important questions that inform treatment guidelines, 
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